David Halpin&refresh | The Medical School

Professor David Halpin

Consultant Physician & Honorary Professor of Respiratory Medicine

D.M.G.Halpin@exeter.ac.uk

Smeall building

Smeall Building, University of Exeter, St Luke's Campus, Heavitree Road, Exeter, EX1 2LU, UK

Overview

Professor Halpin was appointed as a Consultant Physician and Senior Lecturer in Respiratory Medicine in Exeter in 1994. He has a busy clinical practice and for 13 years he was Clinical Lead for the Department in Exeter, overseeing the growth in its clinical and research activity. He is also Honorary Professor of Respiratory Medicine at the Observational and Pragmatic Research Institute (OPRI) in Singapore. He is a member of the Board of Directors of the Global Initiative on Obstructive Lung Diseases (GOLD) and of the GOLD Science Committee. He was the Chairman and Clinical Expert for the COPD Guideline Development Group of the National Institute of Clinical Excellence (NICE) in the UK.

He studied medicine at Brasenose College, Oxford University (first class honours) & St Thomas Hospital Medical School, qualifying in 1986. He was awarded an MRC scholarship to undertake a D.Phil. in the Department of Human Anatomy at Oxford University, between his pre-clinical and clinical training. He trained in respiratory medicine at the Royal Brompton Hospital in London.

He is a Fellow of Royal College Physicians, and a Member of the British Thoracic Society (BTS), European Respiratory Society (ERS) & American Thoracic Society (ATS). He has served on various BTS committees. In 2018 he was elected as a Fellow of ERS in recognition of lifetime excellence and contributions to research, education and clinical leadership in respiratory medicine.

Qualifications

BA Physiological Sciences, First Class, University of Oxford, 1981
DPhil, University of Oxford, 1983
MA, University of Oxford, 1983
MB BS, St Thomas's Hospital Medical School, London University 1986
MRCP, Royal College of Physicians London 1989
FRCP, Royal College of Physicians London, 1999
FERS, European Respiratory Society, 2018

Research

Research interests

His research is focused on clinical aspects of COPD and asthma.

He has led studies on the pharmacological treatment of asthma and COPD, including the effects of long acting-bronchodilators, inhaled corticosteroids and biologic therapies. He has recently led a real world pragmatic RCT examining the benefits of single versus multiple inhaler therapy in COPD. Recent work has also looked at the role of biomarkers as predictors of therapeutic response.

He has also had a longstanding interests in the role of palliative care for patients with COPD and the role of psychological factors in COPD and asthma.

Research projects

MAGNIFY Trial: A pragmatic cluster randomized study evaluating a smart inhaler in patients with COPD
QUEST Study: Predictors of response to Dupilumab in asthma.
CONQUEST: COPD quality improvement program development and cluster randomized RCT to assess efficacy in primary care
TRITON: Phase III study comparing efficacy, safety and tolerability of the fixed dose triple therapy with the fixed dose dual therapy in subjects with COPD

Publications

Books

(2008). Chronic Kidney Disease National Clinical Guideline for Early Identification and Management in Adults in Primary and Secondary Care., Royal College of Physicians. Abstract.

(2006). Anaemia Management in Chronic Kidney Disease National Clinical Guideline for Management in Adults and Children., Royal College of Physicians.

Halpin DMG, Rudolf M, Yıldırım N, Demir T, Turgut Y (2006). Current COPD.

Halpin DMG (2003). Copd Your Questions Answered. Abstract.

Halpin DMG, Michael RMD (2002). Current COPD., Science Press Incorporated.

Halpin DMG (2001). COPD., Mosby Incorporated. Abstract.

Journal articles

Stolbrink M, Thomson H, Hadfield RM, Ozoh OB, Nantanda R, Jayasooria S, Allwood BW, Halpin D, Salvi S, Montes de Oca M, et al (In Press). The Availability, Cost and Affordability of Essential Medicines for Asthma and COPD in Low-Income and Middle-Income Countries: a Systematic Review.

Han MK, Criner GJ, Halpin DMG, Kerwin EM, Tombs L, Lipson DA, Martinez FJ, Wise RA, Singh D (2024). Any Decrease in Lung Function is Associated with Worse Clinical Outcomes: Post Hoc Analysis of the IMPACT Interventional Trial. Chronic Obstructive Pulmonary Diseases Journal of the COPD Foundation, 11(1), 106-113.

Domingo C, Hanania N, Canonica G, Halpin D, Lugogo N, Rhee CK, Altincatal A, Pandit-Abid N, Nash S, Deniz Y, et al (2024). Association of Baseline Lung Function and Likelihood of Oral Corticosteroid Reduction in Patients with OCS-Dependent Severe Asthma. Journal of Allergy and Clinical Immunology, 153(2).

Halpin DMG (2024). Bronchodilator Responsiveness in Asthma and Chronic Obstructive Pulmonary Disease: Time to Stop Chasing Shadows. Am J Respir Crit Care Med, 209(4), 349-351. Author URL.

Ismaila AS, Rothnie KJ, Wood RP, Banks VL, Camidge LJ, Czira A, Compton C, Sharma R, Millard SN, Massey O, et al (2024). Correction: Benefit of prompt initiation of single-inhaler fluticasone furoate, umeclidinium, and vilanterol (FF/UMEC/VI) in patients with COPD in England following an exacerbation: a retrospective cohort study. Respir Res, 25(1). Author URL.

Aaron SD, Montes de Oca M, Celli B, Bhatt SP, Bourbeau J, Criner GJ, DeMeo DL, Halpin DMG, Han MK, Hurst JR, et al (2024). Early Diagnosis and Treatment of Chronic Obstructive Pulmonary Disease: the Costs and Benefits of Case Finding. Am J Respir Crit Care Med, 209(8), 928-937. Author URL.

Ismaila AS, Haeussler K, Malmenäs M, Sharma R, Compton C, Vogelmeier CF, Han MK, Halpin DMG (2023). A Response to: Letter to the Editor Regarding “Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: a Network Meta-analysis”. Advances in Therapy, 40(5), 2556-2561.

Sin DD, Doiron D, Agusti A, Anzueto A, Barnes PJ, Celli BR, Criner GJ, Halpin D, Han MK, Martinez FJ, et al (2023). Air pollution and COPD: GOLD 2023 committee report. Eur Respir J, 61(5). Abstract. Author URL.

Ismaila AS, Rothnie KJ, Wood RP, Banks VL, Camidge LJ, Czira A, Compton C, Sharma R, Millard SN, Massey O, et al (2023). Benefit of prompt initiation of single-inhaler fluticasone furoate, umeclidinium, and vilanterol (FF/UMEC/VI) in patients with COPD in England following an exacerbation: a retrospective cohort study. Respir Res, 24(1). Abstract. Author URL.

Halpin DMG (2023). Clinical Management of COPD in the Real World: can Studies Reveal Errors in Management and Pathways to Improve Patient Care?. Pragmat Obs Res, 14, 51-61. Abstract. Author URL.

Mahler DA, Halpin DMG (2023). Consideration and Assessment of Patient Factors When Selecting an Inhaled Delivery System in COPD. CHEST Journal, 165(2), 323-332.

Halpin DM (2023). Do the 'missing millions' of COPD patients want to be found?. Thorax, 78(6), 531-532. Author URL.

Agustí A, Celli BR, Criner GJ, Halpin D, Anzueto A, Barnes P, Bourbeau J, Han MK, Martinez FJ, Montes de Oca M, et al (2023). Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive Summary. Archivos de Bronconeumología, 59(4), 232-248.

Agustí A, Celli BR, Criner GJ, Halpin D, Anzueto A, Barnes P, Bourbeau J, Han MK, Martinez FJ, de Oca MM, et al (2023). Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive Summary. Respirology, 28(4), 316-338. Author URL.

Agustí A, Celli BR, Criner GJ, Halpin D, Anzueto A, Barnes P, Bourbeau J, Han MK, Martinez FJ, de Oca MM, et al (2023). Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD executive summary. Journal of the Pan African Thoracic Society, 4, 58-80. Abstract. Full text.

Agustí A, Sisó-Almirall A, Roman M, Vogelmeier CF, Anzueto A, Barnes P, Bourbeau J, Celli BR, Criner GJ, Halpin D, et al (2023). Gold 2023: Highlights for primary care. npj Primary Care Respiratory Medicine, 33(1).

Halpin DMG, Dickens AP, Skinner D, Murray R, Singh M, Hickman K, Carter V, Couper A, Evans A, Pullen R, et al (2023). Identification of key opportunities for optimising the management of high-risk COPD patients in the UK using the CONQUEST quality standards: an observational longitudinal study. The Lancet Regional Health - Europe, 29 Abstract.

Corren J, Katelaris CH, Castro M, Maspero JF, Humbert M, Halpin DMG, Altincatal A, Pandit-Abid N, Soler X, Radwan A, et al (2023). Impact of exacerbation history on long-term efficacy of dupilumab in patients with asthma. ERJ Open Research, 9(5), 00037-02023.

Wells JM, Criner GJ, Halpin DMG, Han MK, Jain R, Lange P, Lipson DA, Martinez FJ, Midwinter D, Singh D, et al (2023). Mortality Risk and Serious Cardiopulmonary Events in Moderate-to-Severe COPD: Post Hoc Analysis of the IMPACT Trial. Chronic Obstructive Pulmonary Diseases Journal of the COPD Foundation, 10(1), 33-45.

Ismaila A, Haeussler K, Czira A, Youn J-H, Malmenäs M, Risebrough N, Agarwal J, Nassim M, Sharma R, Compton C, et al (2023). Méta-analyse en réseau sur l’efficacité du fuorate de fluticasone/uméclidinium/vilantérol (FF/UMEC/VI) par rapport aux autres trithérapies dans le traitement de la bronchopneumopathie chronique obstructive (BPCO) : une comparaison des taux annualisés des exacerbations modérées et sévères. Revue des Maladies Respiratoires Actualités, 15(1).

Mahler DA, Halpin DMG (2023). Personalizing Selection of Inhaled Delivery Systems in Chronic Obstructive Pulmonary Disease. Ann Am Thorac Soc, 20(10), 1389-1396. Abstract. Author URL.

Bousquet J, Melén E, Haahtela T, Koppelman GH, Togias A, Valenta R, Akdis CA, Czarlewski W, Rothenberg M, Valiulis A, et al (2023). Rhinitis associated with asthma is distinct from rhinitis alone: the ARIA-MeDALL hypothesis. Allergy, 78(5), 1169-1203. Abstract. Author URL.

Halpin DMG, Mahler DA (2022). A Systematic Review of Published Algorithms for Selecting an Inhaled Delivery System in Chronic Obstructive Pulmonary Disease. Ann Am Thorac Soc, 19(7), 1213-1220. Abstract. Author URL.

Vega-Olivo M, Halpin DMG, Han MK, Hanania NA, Kalhan R, Lipson DA, MacIntyre N, Midwinter D, Stiegler M, Young C, et al (2022). Best Practice Management of Patients with Chronic Obstructive Pulmonary Disease: a Case-Based Review. The Journal for Nurse Practitioners, 18(7), 730-735.

Singh D, Agusti A, Martinez FJ, Papi A, Pavord ID, Wedzicha JA, Vogelmeier CF, Halpin DMG (2022). Blood Eosinophils and Chronic Obstructive Pulmonary Disease: a Global Initiative for Chronic Obstructive Lung Disease Science Committee 2022 Review. Am J Respir Crit Care Med, 206(1), 17-24. Author URL.

Halpin DMG, Rothnie KJ, Banks V, Czira A, Compton C, Wood R, Tritton T, Massey O, Wild R, Snowise N, et al (2022). Comparative Adherence and Persistence of Single-and Multiple-Inhaler Triple Therapies Among Patients with Chronic Obstructive Pulmonary Disease in an English Real-World Primary Care Setting. International Journal of COPD, 17, 2417-2429. Abstract.

Ismaila AS, Haeussler K, Czira A, Tongbram V, Malmenäs M, Agarwal J, Nassim M, Živković-Gojović M, Shen Y, Dong X, et al (2022). Comparative Efficacy of Umeclidinium/Vilanterol Versus Other Bronchodilators for the Treatment of Chronic Obstructive Pulmonary Disease: a Network Meta-Analysis. Advances in Therapy, 39(11), 4961-5010. Abstract.

Ismaila AS, Haeussler K, Czira A, Tongbram V, Malmenas M, Agarwal J, Nassim M, Zivkovic-Gojovic M, Shen Y, Dong X, et al (2022). Comparative Efficacy of Umeclidinium/Vilanterol Versus Other Bronchodilators for the Treatment of Chronic Obstructive Pulmonary Disease: a Network Meta-Analysis (Jul, 10.1007/s12325-022-02234-x, 2022). ADVANCES IN THERAPY, 39(11), 5011-5012. Author URL.

Tabberer M, Jones CE, Kilbride S, Halpin DMG, Lomas DA, Pascoe S, Singh D, Wise RA, Criner GJ, Lange P, et al (2022). Correction to: Single-Inhaler Triple Therapy and Health-Related Quality of Life in COPD: the IMPACT Study (Advances in Therapy, (2020), 37, 9, (3775-3790), 10.1007/s12325-020-01409-8). Advances in Therapy, 39(3). Abstract.

Halpin DMG, Kendall R, Shukla S, Martin A, Shah D, Midwinter D, Beeh KM, Kocks JWH, Jones PW, Compton C, et al (2022). Cost-Effectiveness of Single-versus Multiple-Inhaler Triple Therapy in a UK COPD Population: the INTREPID Trial. International Journal of COPD, 17, 2745-2755. Abstract.

CORREN J, CASTRO M, MASPERO JF, HUMBERT M, HALPIN DM, ALTINCATAL A, PANDIT-ABID N, SOLER X, SIDDIQUI S, JACOB-NARA JA, et al (2022). DUPILUMAB REDUCED EXACERBATIONS AND IMPROVED LUNG FUNCTIONS IN PATIENTS WITH MODERATE-TO-SEVERE ASTHMA AND PRIOR EXACERBATIONS: LIBERTY ASTHMA TRAVERSE STUDY. CHEST Journal, 162(4), a1936-a1938.

Domingo C, Maspero JF, Castro M, Hanania NA, Ford LB, Halpin DMG, Jackson DJ, Daizadeh N, Djandji M, Mitchell CP, et al (2022). Dupilumab Efficacy in Steroid-Dependent Severe Asthma by Baseline Oral Corticosteroid Dose. The Journal of Allergy and Clinical Immunology in Practice, 10(7), 1835-1843.

Bourdin A, Virchow JC, Papi A, Lugogo NL, Bardin P, Antila M, Halpin DMG, Daizadeh N, Djandji M, Ortiz B, et al (2022). Dupilumab efficacy in subgroups of type 2 asthma with high-dose inhaled corticosteroids at baseline. Respiratory Medicine, 202

Cai R, Martin A, Ge Y, Risebrough N, Sharma R, Haeussler K, Compton C, Halpin D, Ismaila A (2022). EE648 Economic Analysis of New Single-Inhaler Triple Therapies in Patients with COPD in the UK. Value in Health, 25(12), s183-s184.

Thompson PJ, Criner GJ, Dransfield MT, Halpin DMG, Han MK, Lipson DA, Maghzal GJ, Martinez FJ, Midwinter D, Singh D, et al (2022). Effect of chronic mucus hypersecretion on treatment responses to inhaled therapies in patients with chronic obstructive pulmonary disease: Post hoc analysis of the IMPACT trial. Respirology, 27(12), 1034-1044. Abstract. Author URL.

Halpin DMG, Rabe AP, Loke WJ, Grieve S, Daniele P, Hwang S, Forsythe A (2022). Epidemiology, Healthcare Resource Utilization, and Mortality of Asthma and COPD in COVID-19: a Systematic Literature Review and Meta-Analyses. J Asthma Allergy, 15, 811-825. Abstract. Author URL.

Ismaila AS, Haeussler K, Czira A, Youn J-H, Malmenas M, Risebrough NA, Agarwal J, Nassim M, Sharma R, Compton C, et al (2022). Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: a Network Meta-Analysis. ADVANCES IN THERAPY, 39(9), 3957-3978. Author URL.

Thomashow B, Stiegler M, Criner GJ, Dransfield MT, Halpin DMG, Han MK, Lange P, Martinez FJ, Midwinter D, Singh D, et al (2022). Higher COPD Assessment Test Score Associated with Greater Exacerbations Risk: a Post Hoc Analysis of the IMPACT Trial. Chronic Obstr Pulm Dis, 9(1), 68-79. Abstract. Author URL.

Mortimer K, de Oca MM, Salvi S, Balakrishnan K, Hadfield RM, Ramirez-Venegas A, Halpin DMG, Obianuju BO, MeiLan KH, Padilla RP, et al (2022). Household air pollution and COPD: cause and effect or confounding by other aspects of poverty?. The International Journal of Tuberculosis and Lung Disease, 26(3), 206-216.

Hanania NA, Maspero JF, Halpin DMG, Jackson DJ, Panettieri RA, Castro M, Domingo C, Daizadeh N, Gall R, Jacob-Nara JA, et al (2022). Improvement in Lung Function with Dupilumab Does Not Predict its Effects on Reducing Asthma Exacerbation. J Asthma Allergy, 15, 851-854. Author URL.

Stolbrink M, Chinouya MJ, Jayasooria S, Nightingale R, Evans-Hill L, Allan K, Allen H, Balen J, Beacon T, Bissell K, et al (2022). Improving Access to Affordable Quality-Assured Inhaled Medicines in Low- and Middle-Income Countries.

Rylance S, Bateman ED, Boulet L, Cohen M, Sony AEL, Halpin DMG, Khoo EM, Marks GB, Masekela R, Mikkelsen B, et al (2022). Key messages and partnerships to raise awareness and improve outcomes for people with asthma and COPD in low- and middle-income countries. International Journal of Tuberculosis and Lung Disease, 26(12), 1106-1108.

Halpin DMG, Vogelmeier CF, Agusti A (2022). Lung Health for All: Chronic Obstructive Lung Disease and World Lung Day 2022. Am J Respir Crit Care Med, 206(6), 669-671. Author URL.

Ohar JA, Ferguson GT, Mahler DA, Drummond MB, Dhand R, Pleasants RA, Anzueto A, Halpin DMG, Price DB, Drescher GS, et al (2022). Measuring Peak Inspiratory Flow in Patients with Chronic Obstructive Pulmonary Disease. INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 17, 79-92. Author URL.

Halpin DMG, Martinez FJ (2022). Pharmacotherapy and Mortality in Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med, 206(10), 1201-1207. Author URL.

Halpin DMG (2022). Precision medicine in chronic obstructive pulmonary disease. Chinese Medical Journal, 135(10), 1156-1162.

Gabrio A, Gunsoy NB, Baio G, Martin A, Paly VF, Risebrough N, Halpin DMG, Singh D, Wise RA, Han MK, et al (2022). Single-Inhaler Triple Therapy in Patients with Advanced COPD: Bayesian Modeling of the Healthcare Resource Utilization Data and Associated Costs from the IMPACT Trial. Int J Chron Obstruct Pulmon Dis, 17, 1633-1642. Abstract. Author URL.

Bardsley S, Criner GJ, Halpin DMG, Han MK, Hanania NA, Hill D, Lange P, Lipson DA, Martinez FJ, Midwinter D, et al (2022). Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus dual therapy in current and former smokers with COPD: IMPACT trial post hoc analysis. Respiratory Medicine, 205

Agusti A, Vogelmeier CF, Halpin DMG (2022). Tackling the global burden of lung disease through prevention and early diagnosis. The Lancet Respiratory Medicine, 10(11), 1013-1015.

Dransfield MT, Criner GJ, Halpin DMG, Han MK, Hartley B, Kalhan R, Lange P, Lipson DA, Martinez FJ, Midwinter D, et al (2022). Time-Dependent Risk of Cardiovascular Events Following an Exacerbation in Patients with Chronic Obstructive Pulmonary Disease: Post Hoc Analysis from the IMPACT Trial. J Am Heart Assoc, 11(18). Abstract. Author URL.

Martinez FJ, Agusti A, Celli BR, Han MK, Allinson JP, Bhatt SP, Calverley P, Chotirmall SH, Chowdhury B, Darken P, et al (2022). Treatment Trials in Young Patients with Chronic Obstructive Pulmonary Disease and Pre-Chronic Obstructive Pulmonary Disease Patients: Time to Move Forward. Am J Respir Crit Care Med, 205(3), 275-287. Abstract. Author URL.

Wells JM, Bhatt SP, Carr TF, Criner GJ, Halpin DM, Han MK, jain R, Kaye MG, Kraft M, Sail L, et al (2022). Une analyse de l’étude IMPACT évaluant la triple thérapie en une seule prise avec Furoate de Fluticasone/Umeclidinium/Vilanterol (FF/UMEC/VI) versus FF/VI et UMEC/VI en utilisant un critère composite d’événement indésirable chez des patients BPCO. Revue des Maladies Respiratoires Actualités, 14(1), 51-52.

Bafadhel M, Barnes N, Bourke SC, Compton C, Criner GJ, Dransfield MT, Halpin DMG, Han MLK, Hartley B, Jones CE, et al (2021). A single blood eosinophil count measurement is as good as two for prediction of ICS treatment response in the IMPACT trial. European Respiratory Journal, 58(3).

Bousquet J, Jutel M, Akdis CA, Klimek L, Pfaar O, Nadeau KC, Eiwegger T, Bedbrook A, Ansotegui IJ, Anto JM, et al (2021). ARIA-EAACI statement on asthma and COVID-19 (June 2, 2020). Allergy, 76(3), 689-697. Author URL.

Mammen MJ, Carr TF, Kraft M, Criner GJ, Dransfield MT, Wells JM, Halpin DMG, Han MK, Jain RG, Kaul V, et al (2021). All-cause mortality by subgroup in patients with chronic obstructive pulmonary disease: Post hoc analysis of the impact trial. Am. J. Respir. Crit. Care Med., 203(9). Abstract. Author URL.

Wells JM, Bhatt SP, Dransfield MT, Carr TF, Kraft M, Criner GJ, Halpin DMG, Han MK, Jain R, Kaye MG, et al (2021). An analysis of the impact trial assessing single-inhaler therapy with fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) versus FF/VI and UMEC/VI using a composite adverse event outcome in patients with copd. Am. J. Respir. Crit. Care Med., 203(9). Abstract. Author URL.

Bourbeau J, Bafadhel M, Barnes NC, Compton C, Di Boscio V, Lipson DA, Jones PW, Martin N, Weiss G, Halpin DMG, et al (2021). Benefit/Risk Profile of Single-Inhaler Triple Therapy in COPD. INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 16, 499-517. Author URL.

Halpin DMG, Vogelmeier CF, Agusti AA (2021). COPD & COVID-19. Archivos de Bronconeumología, 57(3), 162-164.

Halpin DMG, Vogelmeier CF, Agusti A (2021). COVID-19 and COPD: lessons beyond the pandemic. Am J Physiol Lung Cell Mol Physiol, 321(5), L978-L982. Abstract. Author URL.

Bousquet J, Anto JM, Czarlewski W, Haahtela T, Fonseca SC, Iaccarino G, Blain H, Vidal A, Sheikh A, Akdis CA, et al (2021). Cabbage and fermented vegetables: from death rate heterogeneity in countries to candidates for mitigation strategies of severe COVID-19. ALLERGY, 76(3), 735-750. Author URL.

Stanley B, Davis A, Jones R, Julious S, Ryan D, Jackson D, Halpin D, Pinnock H, Quint J, Khunti K, et al (2021). Characteristics of patients in platform C19, a COVID-19 research database combining primary care electronic health record and patient reported information. PLoS One, 16(10). Abstract. Author URL.

Wise RA, Bafadhel M, Crim C, Criner GJ, Day NC, Halpin DMG, Han MK, Lange P, Lipson DA, Martinez FJ, et al (2021). Discordant diagnostic criteria for pneumonia in COPD trials: a review. European Respiratory Review, 30(162). Abstract.

Hanania NA, Mannino DM, Criner GJ, Dransfield MT, Han MLK, Jones CE, Kilbride S, Lomas DA, Martin N, Martinez FJ, et al (2021). Effect of Age on the Efficacy and Safety of Once-Daily Single-Inhaler Triple-Therapy Fluticasone Furoate/Umeclidinium/Vilanterol in Patients with COPD: a Post Hoc Analysis of the Informing the Pathway of COPD Treatment Trial. Chest, 159(3), 985-995. Abstract.

Corren J, Katelaris CH, Castro M, Maspero JF, Ford LB, Halpin DMG, Rice MS, Radwan A, Deniz Y, Rowe PJ, et al (2021). Effect of exacerbation history on clinical response to dupilumab in moderate-to-severe uncontrolled asthma. EUROPEAN RESPIRATORY JOURNAL, 58(4). Author URL.

Halpin DMG, Vogelmeier CF, Mezzi K, Gupta P, Kostikas K, Wedzicha JA (2021). Efficacy of indacaterol/glycopyrronium versus salmeterol/fluticasone in current and ex-smokers: a pooled analysis of ignite trials. ERJ Open Research, 7(1). Abstract.

Han MK, Agusti A, Celli BR, Criner GJ, Halpin DMG, Roche N, Papi A, Stockley RA, Wedzicha J, Vogelmeier CF, et al (2021). From GOLD 0 to Pre-COPD. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 203(4), 414-423. Author URL.

Halpin DMG, Criner GJ, Papi A, Singh D, Anzueto A, Martinez FJ, Agusti AA, Vogelmeier CF (2021). Global Initiative for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease. American Journal of Respiratory and Critical Care Medicine, 203(1), 24-36. Abstract.

Halpin DMG, Worsley S, Ismaila AS, Beeh K-M, Midwinter D, Kocks JWH, Irving E, Marin JM, Martin N, Tabberer M, et al (2021). INTREPID: single- versus multiple-inhaler triple therapy for COPD in usual clinical practice. ERJ OPEN RESEARCH, 7(2). Author URL.

Halpin DM, Worsley S, Ismaila AS, Astrom J, Beeh KM, Brintziki D, Di Boscio V, Kocks J, Marin JM, Tabberer M, et al (2021). INTREPID : efficacité clinique de Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) en inhalateur unique versus triples thérapies en inhalateurs multiples en pratique clinique quotidienne. Revue des Maladies Respiratoires Actualités, 13(1), 102-103.

Meghji J, Mortimer K, Agusti A, Allwood BW, Asher I, Bateman ED, Bissell K, Bolton CE, Bush A, Celli B, et al (2021). Improving lung health in low-income and middle-income countries: from challenges to solutions. LANCET, 397(10277), 928-940. Author URL.

Singh D, Criner GJ, Dransfield MT, Halpin DMG, Han MK, Lange P, Lettis S, Lipson DA, Mannino D, Martin N, et al (2021). InforMing the PAthway of COPD Treatment (IMPACT) trial: fibrinogen levels predict risk of moderate or severe exacerbations. RESPIRATORY RESEARCH, 22(1). Author URL.

Price D, Jones R, Pfister P, Cao H, Carter V, Kemppinen A, Holzhauer B, Kaplan A, Clark A, Halpin DMG, et al (2021). Maximizing Adherence and Gaining New Information for Your Chronic Obstructive Pulmonary Disease (MAGNIFY COPD): Study Protocol for the Pragmatic, Cluster Randomized Trial Evaluating the Impact of Dual Bronchodilator with Add-On Sensor and Electronic Monitoring on Clinical Outcomes. Pragmat Obs Res, 12, 25-35. Abstract. Author URL.

Bourdin A, Virchow J, Papi A, Lugogo N, Halpin D, Daizadeh N, Ortiz B, Djandji M (2021). P066 DUPILUMAB EFFICACY IN PATIENTS WITH TYPE 2 ASTHMA WITH/WITHOUT ALLERGIC PHENOTYPE RECEIVING HIGH-DOSE INHALED CORTICOSTEROIDS. Annals of Allergy Asthma & Immunology, 127(5), s32-s33.

Mahler DA, Halpin DMG (2021). Peak Inspiratory Flow as a Predictive Therapeutic Biomarker in COPD. CHEST, 160(2), 491-498. Author URL.

Han MK, Agusti A, Celli BR, Criner GJ, Halpin DMG, Roche N, Papi A, Stockley RA, Wedzicha J, Vogelmeier CF, et al (2021). Pre-Chronic Obstructive Pulmonary Disease: Toward the Limits of the Spirometric Funnel Reply. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 204(1), 112-112. Author URL.

Han MK, Criner GJ, Dransfield MT, Halpin DMG, Jones CE, Kilbride S, Lange P, Lettis S, Lipson DA, Lomas DA, et al (2021). Prognostic value of clinically important deterioration in copd: Impact trial analysis. ERJ Open Research, 7(1). Abstract.

Humbert M, Bourdin A, Papadopoulos NG, Holgate ST, Hanania NA, Halpin DMG, Chapman KR, Gavornikova M, Price DB, Kaplan A, et al (2021). Reducing the hidden burden of severe asthma: recognition and referrals from primary practice. JOURNAL OF ASTHMA, 58(7), 849-854. Author URL.

Mapel DW, Bogart M, Jain R, Criner GJ, Dransfield MT, Gaeckle N, Gotfried M, Halpin DMG, Han MK, Kaul V, et al (2021). Reduction in emergency department (ED) visits in patients with chronic obstructive pulmonary disease (Copd): Analysis of the impact trial. Am. J. Respir. Crit. Care Med., 203(9). Abstract. Author URL.

Jones R, Davis A, Stanley B, Julious S, Ryan D, Jackson DJ, Halpin DMG, Hickman K, Pinnock H, Quint JK, et al (2021). Risk Predictors and Symptom Features of Long COVID Within a Broad Primary Care Patient Population Including Both Tested and Untested Patients. Pragmat Obs Res, 12, 93-104. Abstract. Author URL.

Mammen MJ, Carr TF, Kraft M, Criner GJ, Dransfield MT, Wells JM, Halpin DMG, Han MK, Hartley B, Jain R, et al (2021). Risk of all-cause mortality during and after severe exacerbations in patients with chronic obstructive pulmonary disease (Copd): Post hoc analysis of the impact trial. Am. J. Respir. Crit. Care Med., 203(9). Abstract. Author URL.

Dransfield MT, Crim C, Criner GJ, Day NC, Halpin DMG, Han MLK, Elaine Jones C, Kilbride S, LaFon D, Lipson DA, et al (2021). Risk of exacerbation and pneumonia with single-inhaler triple versus dual therapy in IMPACT. Annals of the American Thoracic Society, 18(5), 788-798. Abstract.

Corbetta L, Fabbri LM, Halpin D, Cruz AA, Zanconato S (2021). Stand on the Same Side Against Covid – 19: Ics-Containing Products in Treatment Covid-19 Patients with Asthma and COPD. Substantia, 1234-1234. Abstract.

Halpin DMG, Criner GJ, Dransfield MT, Han MLK, Hartley B, Harvey C, Jones CE, Kato M, Lange P, Lettis S, et al (2021). Triple Versus Dual Combination Therapy in Chronic Obstructive Pulmonary Disease in Asian Countries: Analysis of the IMPACT Trial. Pulmonary Therapy, 7(1), 101-118. Abstract.

Ming SWY, Haughney J, Ryan D, Small I, Lavorini F, Papi A, Singh D, Halpin DMG, Hurst JR, Patel S, et al (2020). A comparison of the real-life clinical effectiveness of the leading licensed ics/laba combination inhalers in the treatment for copd. International Journal of COPD, 15, 3093-3103. Abstract.

To T, Viegi G, Cruz A, Taborda-Barata L, Asher I, Behera D, Bennoor K, Boulet L-P, Bousquet J, Camargos P, et al (2020). A global respiratory perspective on the COVID-19 pandemic: commentary and action proposals. Eur Respir J, 56(1). Abstract. Author URL.

Kerkhof M, Chaudhry I, Pavord ID, Miravitlles M, Kook Rhee C, Halpin DMG, Usmani OS, Jones R, Kocks J, Alacqua M, et al (2020). Blood eosinophil count predicts treatment failure and hospital readmission for COPD. ERJ Open Res, 6(4). Abstract. Author URL.

(2020). COVID-19 pandemic alert: time to focus on lung health-Beijing call to action for lung health promotion. Journal of Thoracic Disease, 12(6), 3238-3241.

Halpin DMG, Hamelmann EH, Frith PA, Moroni-Zentgraf PM, van Hecke B, Unseld A, Kerstjens HAM, Szefler SJ (2020). Comparative Responses in Lung Function Measurements with Tiotropium in Adolescents and Adults, and Across Asthma Severities: a Post Hoc Analysis. Pulmonary Therapy, 6(1), 131-140.

Rabe KF, Halpin DMG, Han MK, Miravitlles M, Singh D, Groenke L, Voss F, Martinez FJ (2020). Composite endpoints in COPD: clinically important deterioration in the UPLIFT trial. RESPIRATORY RESEARCH, 21(1). Author URL.

Halpin DMG, Faner R, Sibila O, Badia JR, Agusti A (2020). Do chronic respiratory diseases or their treatment affect the risk of SARS-CoV-2 infection?. The Lancet Respiratory Medicine, 8(5), 436-438.

Kaplan A, Szefler SJ, Halpin DMG (2020). Impact of comorbid conditions on asthmatic adults and children. npj Primary Care Respiratory Medicine, 30(1). Abstract.

Singh D, Criner GJ, Dransfield MT, Halpin DMG, Han MK, Jones CE, Kilbride S, Lange P, Lomas DA, Martinez FJ, et al (2020). InforMing the PAthway of COPD Treatment (étude IMPACT) : triple thérapie en un inhalateur unique (Furoate de Fluticasone/Umeclidinium/Vilanterol) comparée à Furoate de Fluticasone/Vilanterol et Umeclidinium/Vilanterol chez les patients atteints de bronchopneumopathie chronique obstructive (BPCO) : analyse basée sur les traitements de la BPCO à l’inclusion. Revue des Maladies Respiratoires Actualités, 12(1), 191-192.

Singh D, Halpin DMG (2020). Inhaled corticosteroids and COVID-19-related mortality: confounding or clarifying?. The Lancet Respiratory Medicine, 8(11), 1065-1066.

Halpin DMG, Singh D, Hadfield RM (2020). Inhaled corticosteroids and COVID-19: a systematic review and clinical perspective. EUROPEAN RESPIRATORY JOURNAL, 55(5). Author URL.

Halpin DM, Worsley S, Ismaila AS, Astrom J, Beeh KM, Brintziki D, Tabberer M, Di Boscio V, Compton C, Kocks J, et al (2020). Intrepid: Clinical effectiveness of once-daily single-inhaler fluticasone furoate/umeclidinium/vilanterol versus multiple-inhaler triple therapy in usual clinical practice. Am. J. Respir. Crit. Care Med., 201(1). Abstract. Author URL.

Bousquet J, Cristol JP, Czarlewski W, Anto JM, Martineau A, Haahtela T, Fonseca SC, Iaccarino G, Blain H, Fiocchi A, et al (2020). Nrf2-interacting nutrients and COVID-19: time for research to develop adaptation strategies. Clinical and Translational Allergy, 10(1). Abstract.

Halpin D, Korn S, Matucci A, Bourdin A, Daizadeh N, Ortiz B, Djandji M, Deniz Y, Rowe P (2020). P221 EFFICACY OF DUPILUMAB IN PATIENTS WITH ASTHMA WITH/WITHOUT SUBSTANTIAL REDUCTION IN FRACTIONAL EXHALED NITRIC OXIDE. Annals of Allergy Asthma & Immunology, 125(5).

Lipson DA, Crim C, Criner GJ, Day NC, Dransfield MT, Halpin DMG, Han MK, Jones CE, Kilbride S, Lange P, et al (2020). Reduction in All-Cause Mortality with Fluticasone Furoate/Umeclidinium/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med, 201(12), 1508-1516. Abstract. Author URL.

Tabberer M, Jones CE, Kilbride S, Halpin DMG, Lomas DA, Pascoe S, Singh D, Wise RA, Criner GJ, Lange P, et al (2020). Single-Inhaler Triple Therapy and Health-Related Quality of Life in COPD: the IMPACT Study. Advances in Therapy, 37(9), 3775-3790. Abstract.

Day NC, Kumar S, Criner G, Dransfield M, Halpin DMG, Han MK, Jones CE, Kaisermann MC, Kilbride S, Lange P, et al (2020). Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol and umeclidinium/vilanterol in patients with COPD: Results on cardiovascular safety from the IMPACT trial. Respiratory Research, 21(1). Abstract.

Corbetta L, Fabbri LM, Halpin D, Cruz AA, Zanconato S (2020). Stand on the Same Side Against Covid - 19: Ics-Containing Products in Treatment Covid-19 Patients with Asthma and COPD. Substantia, 4(1).

Halpin DMG, Dransfield MT, Han MLK, Elaine Jones C, Kilbride S, Lange P, Lipson DA, Lomas DA, Martinez FJ, Pascoe S, et al (2020). The effect of exacerbation history on outcomes in the impact trial. European Respiratory Journal, 55(6). Abstract.

Han MLK, Criner GJ, Dransfield MT, Halpin DMG, Elaine Jones C, Kilbride S, Lange P, Lettis S, Lipson DA, Lomas DA, et al (2020). The effect of inhaled corticosteroid withdrawal and baseline inhaled treatment on exacerbations in the IMPACT study a randomized, double-blind, multicenter clinical trial. American Journal of Respiratory and Critical Care Medicine, 202(9), 1237-1243. Abstract.

FitzGerald JM, Buhl R, Casale TB, Jugovic B, Zaremba-Pechmann L, Halpin DMG (2020). Tiotropium add-on therapy reduces seasonal peaks of asthma worsening in adults with symptomatic severe asthma. EUROPEAN RESPIRATORY JOURNAL, 55(1). Author URL.

Halpin DMG (2020). What is Asthma Chronic Obstructive Pulmonary Disease Overlap?. Clinics in Chest Medicine, 41(3), 395-403. Abstract.

Price DB, Bosnic-Anticevich S, Pavord ID, Roche N, Halpin DMG, Bjermer L, Usmani OS, Brusselle G, Ming SWY, Rastogi S, et al (2019). Association of elevated fractional exhaled nitric oxide concentration and blood eosinophil count with severe asthma exacerbations. Clinical and Translational Allergy, 9(1). Abstract.

Pascoe S, Barnes N, Brusselle G, Compton C, Criner GJ, Dransfield MT, Halpin DMG, Han MLK, Hartley B, Lange P, et al (2019). Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial. The Lancet Respiratory Medicine, 7(9), 745-756. Abstract.

Pascoe S, Barnes N, Compton C, Hilton E, Van Der Valk RJP, Brusselle G, Criner G, Dransfield M, Halpin DMG, Han MK, et al (2019). Bzlood eosinophil counts and treatment response in COPD: Analyses of IMPACT. Pneumologie, 73(SUPPPL. 1). Abstract.

Stockley RA, Halpin DMG, Celli BR, Singh D (2019). Chronic Obstructive Pulmonary Disease Biomarkers and Their Interpretation. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 199(10), 1195-1204. Author URL.

Halpin D (2019). Chronic Obstructive Pulmonary Disease and Work: is it Time to Stop?. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 200(10), 1195-1197. Author URL.

Worsley S, Snowise N, Halpin DMG, Midwinter D, Ismaila AS, Irving E, Sansbury L, Tabberer M, Leather D, Compton C, et al (2019). Clinical effectiveness of once-daily fluticasone furoate/umeclidinium/ vilanterol in usual practice: the COPD INTREPID study design. ERJ Open Research, 5(4). Abstract.

Lipson DA, Barnhart F, Crim C, Jones CE, Boucot I, Brealey N, Kilbride S, Criner G, Dransfield M, Halpin DMG, et al (2019). Comparison of LAMA/LABA vs. ICS/LABA in high risk COPD patients: Pre-specified analysis on lung function and health status from the IMPACT trial. Pneumologie, 73(SUPPPL. 1). Abstract.

Stockley RA, Halpin D, Celli BR, Singh D (2019). Confounding Factors Affecting sRAGE as a Biomarker for Chronic Obstructive Pulmonary Disease Reply. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 200(1), 114-115. Author URL.

Ismaila AS, Risebrough N, Schroeder M, Shah D, Martin A, Goodall EC, Ndirangu K, Criner G, Dransfield M, Halpin DMG, et al (2019). Cost-Effectiveness of Once-Daily Single-Inhaler Triple Therapy in COPD: the IMPACT Trial. INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 14, 2681-2695. Author URL.

Criner GJ, Martinez FJ, Aaron S, Agusti A, Anzueto A, Bafadhel M, Barnes PJ, Bourbeau J, Chen R, Ewig J, et al (2019). Current Controversies in Chronic Obstructive Pulmonary Disease a Report from the Global Initiative for Chronic Obstructive Lung Disease Scientific Committee. ANNALS OF THE AMERICAN THORACIC SOCIETY, 16(1), 29-39. Author URL.

Halpin DMG, de Jong HJI, Carter V, Skinner D, Price D (2019). Distribution, Temporal Stability and Appropriateness of Therapy of Patients with COPD in the UK in Relation to GOLD 2019. EClinicalMedicine, 14, 32-41. Abstract.

Van Der Valk RJ, Hilton EC, Criner GJ, Dransfield MT, Halpin DM, Han MK, Jones CE, Kilbride S, Lange P, Martinez FJ, et al (2019). Effets du traitement FF/UMEC/VI versus FF/VI et UMEC/VI chez les patients BPCO réversibles et non réversibles : analyses de l’étude IMPACT. Revue des Maladies Respiratoires, 36

Lipson DA, Barnhart F, Boucot I, Naya I, Crim C, Jones CE, Brealey N, Kilbride S, Criner G, Dransfield M, et al (2019). Exacerbation outcomes with LAMA/LABA and ICS/LABA in high risk COPD patients in the IMPACT trial. Pneumologie, 73(SUPPPL. 1). Abstract.

Singh SJ, Halpin DMG, Salvi S, Kirenga BJ, Mortimer K (2019). Exercise and pulmonary rehabilitation for people with chronic lung disease in LMICs: challenges and opportunities. LANCET RESPIRATORY MEDICINE, 7(12), 1002-1004. Author URL.

Singh D, Agusti A, Anzueto A, Barnes PJ, Bourbeau J, Celli BR, Criner GJ, Frith P, Halpin DMG, Han M, et al (2019). Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: the GOLD science committee report 2019. EUROPEAN RESPIRATORY JOURNAL, 53(5). Author URL.

Bourdin A, Halpin DM, Jones CE, Lettis S, Lange P, Lomas D, Pascoe S, Quasny H, Saïl L, Singh D, et al (2019). InforMing the PAthway of COPD Treatment (étude IMPACT) – Triple thérapie en un inhalateur unique (FF/UMEC/VI) comparée à FF/VI et UMEC/VI chez les patients atteints de BPCO : résultats basés sur une analyse de la région Europe de l’Ouest (Australie, Belgique, République Tchèque, Danemark, Finlande, France, Allemagne, Pays-Bas, Norvège, Pologne, Roumanie, Espagne, Suisse, Royaume-Uni). Revue des Maladies Respiratoires, 36, a99-a100.

Singh D, Criner GJ, Dransfield MT, Halpin DMG, Han MK, Jones CE, Kilbride S, Lange P, Lomas DA, Martinez FJ, et al (2019). InforMing the pathway of COPD treatment (The IMPACT study): Single inhaler triple therapy (fluticasone furoate/umeclidinium/vilanterol) versus fluticasone furoate/vilanterol and umeclidinium/vilanterol in patients with COPD: an analysis based on baseline COPD medication use. Am. J. Respir. Crit. Care Med., 199(9). Abstract. Author URL.

Halpin DMG, Celli BR, Criner GJ, Frith P, Victorina López Varela M, Salvi S, Vogelmeier CF, Chen R, Mortimer K, Montes de Oca M, et al (2019). It is time for the world to take COPD seriously: a statement from the GOLD board of directors. European Respiratory Journal, 54(1).

Hartley B, Criner GJ, Dransfield MT, Halpin DMG, Han MK, Jones CE, Kilbride S, Lange P, Lipson DA, Lomas DA, et al (2019). Misinterpretation of time-to-first event curves can lead to inappropriate treatment. EUROPEAN RESPIRATORY JOURNAL, 54(3). Author URL.

Hartley B, Criner GJ, Dransfield MT, Halpin DMG, Han MLK, Elaine Jones C, Kilbride S, Lange P, Lipson DA, Lomas DA, et al (2019). Misinterpretation of time-to-first event curves can lead to inappropriate treatment. European Respiratory Journal, 54(3).

Halpin DMG, Meltzer EO, Pisternick-Ruf W, Moroni-Zentgraf P, Engel M, Zaremba-Pechmann L, Casale T, FitzGerald JM (2019). Peak expiratory flow as an endpoint for clinical trials in asthma: a comparison with FEV1. RESPIRATORY RESEARCH, 20 Author URL.

Lipson DA, Criner GJ, Day N, Kilbride S, Midwinter D, Dransfield MT, Halpin DM, Han MK, Jones C, Manchester P, et al (2019). Reduction in the risk of all-cause mortality with fluticasone furoate/umeclidinium/vilanterol compared to umeclidinium/vilanterol in IMPACT including previously missing or censored vital status data. Am. J. Respir. Crit. Care Med., 199(9). Abstract. Author URL.

Dransfield M, Crim C, Jones CE, Criner G, Halpin DMG, Han MK, Kilbride S, Lange P, Lipson DA, Lomas DA, et al (2019). Risk of Exacerbation and Pneumonia with Single Inhaler Triple versus Dual Therapie in IMPACT. Pneumologie, 73(SUPPPL. 1). Abstract.

Halpin DMG, Celli BR, Criner GJ, Frith P, López Varela MV, Salvi S, Vogelmeier CF, Chen R, Mortimer K, Montes de Oca M, et al (2019). The GOLD Summit on chronic obstructive pulmonary disease in low- and middle-income countries. International Journal of Tuberculosis and Lung Disease, 23(11), 1131-1141. Abstract.

Miravitlles M, Roche N, Cardoso J, Halpin D, Aisanov Z, Kankaanranta H, Kobližek V, Śliwiński P, Bjermer L, Tamm M, et al (2018). Chronic obstructive pulmonary disease guidelines in Europe: a look into the future. Respir Res, 19(1). Abstract. Author URL.

Halpin DMG, FitzGerald JM, Engel M, Moroni-Zentgraf P, Sigmund R, Meltzer EO, Casale TB (2018). Comparison of PEF vs. FEV1 endpoints in trials with tiotropium in adults and adolescents with moderate or severe symptomatic asthma. J. Allergy Clin. Immunol., 141(2 Supplement 1). Abstract.

Tashkin DP, Miravitlles M, Celli BR, Metzdorf N, Mueller A, Halpin DMG, Anzueto A (2018). Concomitant inhaled corticosteroid use and the risk of pneumonia in COPD: a matched-subgroup post hoc analysis of the UPLIFT® trial. RESPIRATORY RESEARCH, 19 Author URL.

Moroni-Zentgraf P, Usmani OS, Halpin DMG (2018). Inhalation Devices. CANADIAN RESPIRATORY JOURNAL, 2018 Author URL.

Lipson DA, Barnhart F, Brealey N, Brooks J, Criner GJ, Day NC, Dransfield MT, Halpin DMG, Han MK, Jones CE, et al (2018). Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD. N Engl J Med, 378(18), 1671-1680. Abstract. Author URL.

Halpin DMG (2018). Palliative Care for Chronic Obstructive Pulmonary Disease Signs of Progress, but Still a Long Way to Go. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 198(11), 1356-1358. Author URL.

Halpin DMG (2018). Palliative care for people with COPD: effective but underused. EUROPEAN RESPIRATORY JOURNAL, 51(2). Author URL.

Rabe KF, Halpin D, Martinez F, Singh D, Han MK, Zehendner CM, Gronke L, Voss F, Miravittlles M (2018). Relative timing of clinically important deterioration and related long-term outcomes in COPD: a post hoc analysis of the UPLIFT study. Pneumologie, 72(Supplement 1). Abstract.

Halpin DMG, Birk R, Brealey N, Criner GJ, Dransfield MT, Hilton E, Lomas DA, Zhu CQ, Lipson DA (2018). Single-inhaler triple therapy in symptomatic COPD patients: FULFIL subgroup analyses. ERJ Open Research, 4(2). Abstract.

Halpin DMG (2018). The role of tiotropium+olodaterol dual bronchodilator therapy in the management of chronic obstructive pulmonary disease. Tuberculosis and Respiratory Diseases, 81(1), 13-18. Abstract.

Halpin DMG (2018). Therapeutic Role of Tiotropium in Chronic Obstructive Airways Diseases. Barcelona Respiratory Network, 4(2).

FitzGerald JM, Buhl R, Casale TB, El Azzi G, Engel M, Sigmund R, Halpin DM (2018). Tiotropium respimat reduces episodes of asthma worsening in primotina-asthma Irrespective of Baseline Characteristics or Season. Am. J. Respir. Crit. Care Med., 197(MeetingAbstracts). Abstract. Author URL.

Halpin DMG (2018). Understanding irrationality: the key to changing behaviours and improving management of respiratory diseases?. LANCET RESPIRATORY MEDICINE, 6(10), 737-739. Author URL.

Williamson GR, O'Connor A, Chamberlain C, Halpin D (2018). mHealth resources for asthma and pregnancy care: Methodological issues and social media recruitment. A discussion paper. J Adv Nurs, 74(10), 2442-2449. Abstract. Author URL.

Halpin DMG, Decramer M, Celli BR, Mueller A, Metzdorf N, Tashkin DP (2017). Effect of a single exacerbation on decline in lung function in COPD. Respiratory Medicine, 128, 85-91. Abstract.

Halpin D (2017). GOLD 2017 report brings new recommendations on assessing chronic obstructive pulmonary disease. BRITISH JOURNAL OF HOSPITAL MEDICINE, 78(3), 129-129. Author URL.

Vogelmeier CF, Criner GJ, Martinez FJ, Anzueto A, Barnes PJ, Bourbeau J, Celli BR, Chen R, Decramer M, Fabbri LM, et al (2017). Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary. Respirology, 22(3), 575-601. Abstract.

Vogelmeier CF, Criner GJ, Martinez FJ, Anzueto A, Barnes PJ, Bourbeau J, Celli BR, Chen R, Decramer M, Fabbri LM, et al (2017). Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 195(5), 557-582. Author URL.

Vogelmeier CF, Criner GJ, Martinez FJ, Anzueto A, Barnes PJ, Bourbeau J, Celli BR, Chen R, Decramer M, Fabbri LM, et al (2017). Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary. EUROPEAN RESPIRATORY JOURNAL, 49(3). Author URL.

Vogelmeier CF, Criner GJ, Martinez FJ, Anzueto A, Barnes PJ, Bourbeau J, Celli BR, Chen R, Decramer M, Fabbri LM, et al (2017). Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary. ARCHIVOS DE BRONCONEUMOLOGIA, 53(3), 128-149. Author URL.

Vogelmeier CF, Criner GJ, Martinez FJ, Anzueto A, Barnes PJ, Bourbeau J, Celli BR, Chen R, Decramer M, Fabbri LM, et al (2017). Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary (vol 49, 1700214, 2017). EUROPEAN RESPIRATORY JOURNAL, 49(6). Author URL.

Vogelmeier CF, Criner GJ, Martinez FJ, Anzueto A, Barnes PJ, Bourbeau J, Celli BR, Chen R, Decramer M, Fabbri LM, et al (2017). Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary (vol 53, pg 128, 2017). ARCHIVOS DE BRONCONEUMOLOGIA, 53(7), 411-412. Author URL.

Halpin DMG, Miravitlles M, Metzdorf N, Celli B (2017). Impact and prevention of severe exacerbations of COPD: a review of the evidence. INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 12, 2891-2908. Author URL.

Thomas M, Halpin DMG, Miravitlles M (2017). When is dual bronchodilation indicated in COPD?. INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 12, 2291-2305. Author URL.

Halpin DM, Kaplan AG, Russell RK (2017). Why choose tiotropium for my patient? a comprehensive review of actions and outcomes versus other bronchodilators. RESPIRATORY MEDICINE, 128, 28-41. Author URL.

Miravitlles M, Vogelmeier C, Roche N, Halpin D, Cardoso J, Chuchalin AG, Kankaanranta H, Sandström T, Śliwiński P, Zatloukal J, et al (2016). A review of national guidelines for management of COPD in Europe. Eur Respir J, 47(2), 625-637. Abstract. Author URL.

Halpin D, Holmes S, Calvert J, McInerney D (2016). Case finding for chronic obstructive pulmonary disease in people attending long-term condition clinics in primary care. Chron Respir Dis, 13(4), 337-343. Abstract. Author URL.

Singh D, Roche N, Halpin D, Agusti A, Wedzicha JA, Martinez FJ (2016). Current Controversies in the Pharmacological Treatment of Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med, 194(5), 541-549. Abstract. Author URL.

Lange P, Halpin DM, O’donnell DE, Macnee W (2016). Diagnosis, assessment, and phenotyping of COPD: beyond FEV<inf>1</inf>. International Journal of COPD, 11, 3-12. Abstract.

Halpin DMG, Vogelmeier C, Pieper MP, Metzdorf N, Richard F, Anzueto A (2016). Effect of tiotropium on COPD exacerbations: a systematic review. RESPIRATORY MEDICINE, 114, 1-8. Author URL.

Halpin DMG, Kerkhof M, Soriano JB, Mikkelsen H, Price DB (2016). Eligibility of real-life patients with COPD for inclusion in trials of inhaled long-acting bronchodilator therapy. RESPIRATORY RESEARCH, 17 Author URL.

Hyland ME, Halpin DMG, Blake S, Seamark C, Pinnuck M, Ward D, Whalley B, Greaves CJ, Hawkins AL, Seamark D, et al (2016). Preference for different relaxation techniques by COPD patients: Comparison between six techniques. International Journal of COPD, 11(1), 2315-2319. Abstract.

Dahl R, Engel M, Dusser D, Halpin D, Kerstjens HAM, Zaremba-Pechmann L, Moroni-Zentgraf P, Busse WW, Bateman ED (2016). Safety and tolerability of once-daily tiotropium Respimat(®) as add-on to at least inhaled corticosteroids in adult patients with symptomatic asthma: a pooled safety analysis. Respir Med, 118, 102-111. Abstract. Author URL.

Paggiaro P, Halpin DMG, Buhl R, Engel M, Zubek VB, Blahova Z, Moroni-Zentgraf P, Pizzichini E (2016). The Effect of Tiotropium in Symptomatic Asthma Despite Low- to Medium-Dose Inhaled Corticosteroids: a Randomized Controlled Trial. Journal of Allergy and Clinical Immunology: in Practice, 4(1), 104-113.e2. Abstract.

Halpin DMG (2016). Tiotropium in asthma: What is the evidence and how does it fit in?. World Allergy Organization Journal, 9(1). Abstract.

Halpin D, Banks L, Martello A (2016). Working together to go ‘beyond the pill’: Building a virtuous network of collaborators. BMJ Innovations, 2(1), 1-3.

Halpin DMG, Tashkin DP, Celli BR, Leimer I, Metzdorf N, Decramer M (2015). Effect of Tiotropium on Outcomes in Patients with COPD, Categorized Using the New GOLD Grading System: Results of the UPLIFT® Randomized Controlled Trial. Chronic Obstructive Pulmonary Diseases Journal of the COPD Foundation, 2(3), 236-251.

Devillier P, Dusser D, Halpin D, Bateman E, Paggiaro P, Bleecker E, Engel M, Moroni-Zentgraf P, Schmidt H, Kerstjens H, et al (2015). Le tiotropium Respimat en traitement bronchodilatateur additionnel d’un traitement de fond par CSI±LABA réduit le risque d’exacerbation chez les patients asthmatiques adultes non contrôlés. Revue des Maladies Respiratoires, 32

Saleh A, López-Campos JL, Hartl S, Pozo-Rodríguez F, Roberts CM (2015). The Effect of Incidental Consolidation on Management and Outcomes in COPD Exacerbations: Data from the European COPD Audit. PLOS ONE, 10(7), e0134004-e0134004.

Halpin DMG, Dahl R, Hallmann C, Mueller A, Tashkin D (2015). Tiotropium HandiHaler® and Respimat® in COPD: a pooled safety analysis. INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 10, 239-259. Author URL.

Calverley P, Hallmann C, Metzdorf N, Grnke L, Mueller A, Halpin D (2015). Tiotropium efficacy and exacerbation risk in patients with different blood eosinophil levels. Eur. Respir. J., 46(SUPPL. 59). Abstract. Author URL.

Halpin D, Hyland M, Blake S, Seamark C, Pinnuck M, Ward D, Whalley B, Greaves C, Hawkins A, Seamark D, et al (2015). Understanding fear and anxiety in patients at the time of an exacerbation of chronic obstructive pulmonary disease: a qualitative study. JRSM Open, 6(12). Abstract. Author URL.

Sarran C, Halpin D, Levy ML, Prigmore S, Sachon P (2014). A retrospective study of the impact of a telephone alert service (Healthy Outlook) on hospital admissions for patients with chronic obstructive pulmonary disease. NPJ Prim Care Respir Med, 24 Abstract. Author URL.

Tashkin DP, Li N, Kleerup EC, Halpin D, Celli B, Decramer M, Elashoff R (2014). Acute bronchodilator responses decline progressively over 4 years in patients with moderate to very severe COPD. Respir Res, 15(1). Abstract. Author URL.

Jones RCM, Price D, Ryan D, Sims EJ, von Ziegenweidt J, Mascarenhas L, Burden A, Halpin DMG, Winter R, Hill S, et al (2014). Opportunities to diagnose chronic obstructive pulmonary disease in routine care in the UK: a retrospective study of a clinical cohort. The Lancet Respiratory Medicine, 2(4), 267-276. Abstract.

Halpin DMG, Quint JK (2014). The WISDOM of inhaled corticosteroids in COPD. THORAX, 69(12), 1071-1072. Author URL.

Tashkin DP, Li N, Halpin D, Kleerup E, Decramer M, Celli B, Elashoff R (2013). Annual rates of change in pre- vs. post-bronchodilator FEV1 and FVC over 4 years in moderate to very severe COPD. Respir Med, 107(12), 1904-1911. Abstract. Author URL.

Verceles AC, Lechner EJ, Halpin D, Scharf SM (2013). The association between comorbid illness, colonization status, and acute hospitalization in patients receiving prolonged mechanical ventilation. Respir Care, 58(2), 250-256. Abstract. Author URL.

Wise RA, Anzueto A, Cotton D, Dahl R, Devins T, Disse B, Dusser D, Joseph E, Kattenbeck S, Koenen-Bergmann M, et al (2013). Tiotropium Respimat Inhaler and the Risk of Death in COPD. New England Journal of Medicine, 369(16), 1491-1501.

Small N, Gardiner C, Barnes S, Gott M, Halpin D, Payne S, Seamark D (2012). "You get old, you get breathless, and you die": chronic obstructive pulmonary disease in Barnsley, UK. Health Place, 18(6), 1396-1403. Abstract. Author URL.

Tashkin DP, Wang HJ, Halpin D, Kleerup EC, Connett J, Li N, Elashoff R (2012). Comparison of the variability of the annual rates of change in FEV <inf>1</inf> determined from serial measurements of the pre- versus post-bronchodilator FEV <inf>1</inf> over 5 years in mild to moderate COPD: Results of the lung health study. Respiratory Research, 13 Abstract.

Barnes S, Gardiner C, Gott M, Payne S, Chady B, Small N, Seamark D, Halpin D (2012). Enhancing patient-professional communication about end-of-life issues in life-limiting conditions: a critical review of the literature. J Pain Symptom Manage, 44(6), 866-879. Abstract. Author URL.

Halpin DMG, Decramer M, Celli B, Kesten S, Liu D, Tashkin DP (2012). Exacerbation frequency and course of COPD. International Journal of COPD, 7, 653-661. Abstract.

Hyland ME, Whalley B, Halpin DMG, Greaves CJ, Seamark C, Blake S, Pinnuck M, Ward D, Hawkins AL, Seamark D, et al (2012). Frequency of non-asthma GP visits predicts asthma exacerbations: an observational study in general practice. Primary Care Respiratory Journal, 21(4), 405-411. Abstract.

Hyland ME, Whalley B, Halpin DMG, Greaves CJ, Seamark C, Blake S, Pinnuck M, Ward D, Hawkins A, Seamark D, et al (2012). Frequency of non-asthma GP visits predicts asthma exacerbations: an observational study in general practice. Primary Care Respiratory Journal

Seamark D, Blake S, Seamark S, Hyland M, Greaves CJ, Pinnuck M, Ward D, Hawkins A, Halpin D (2012). Is hospitalization for COPD an opportunity for Advance Care Planning? a qualitative study. Primary Care Respiratory Journal, 21(3), 261-266. Abstract.

Halpin DMG, Laing-Morton T, Spedding S, Levy ML, Coyle P, Lewis J, Newbold P, Marno P (2011). A randomised controlled trial of the effect of automated interactive calling combined with a health risk forecast on frequency and severity of exacerbations of COPD assessed clinically and using EXACT PRO. Primary Care Respiratory Journal, 20(3), 324-331. Abstract.

Halpin DMG, Gray J, Edwards SJ, Morais J, Singh D (2011). Budesonide/formoterol vs. salmeterol/fluticasone in COPD: a systematic review and adjusted indirect comparison of pneumonia in randomised controlled trials. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 65(7), 764-774. Author URL.

Halpin DMG (2011). Improving the management of COPD. BMJ, 342(7801).

Halpin DMG, Decramer M, Celli B, Kesten S, Leimer I, Tashkin DP (2011). Risk of Nonlower Respiratory Serious Adverse Events Following COPD Exacerbations in the 4-year UPLIFT® Trial. LUNG, 189(4), 261-268. Author URL.

Marno P, Chalder M, Laing-Morton T, Levy M, Sachon P, Halpin D (2010). Can a health forecasting service offer COPD patients a novel way to manage their condition?. Journal of Health Services Research and Policy, 15(3), 150-155. Abstract.

Gardiner C, Gott M, Payne S, Small N, Barnes S, Halpin D, Ruse C, Seamark D (2010). Exploring the care needs of patients with advanced COPD: an overview of the literature. Respir Med, 104(2), 159-165. Abstract. Author URL.

Halpin DMG (2010). Lessons from the major studies in COPD: Problems and pitfalls in translating research evidence into practice. Primary Care Respiratory Journal, 19(2), 170-179. Abstract.

Gardiner C, Barnes S, Small N, Gott M, Payne S, Seamark D, Halpin D (2010). Reconciling informed consent and 'do no harm': ethical challenges in palliative-care research and practice in chronic obstructive pulmonary disease. Palliat Med, 24(5), 469-472. Abstract. Author URL.

Gott M, Gardiner C, Small N, Payne S, Seamark D, Halpin D, Ruse C, Barnes S (2010). The effect of the Shipman murders on clinician attitudes to prescribing opiates for dyspnoea in end-stage chronic obstructive pulmonary disease in England. Progress in Palliative Care, 18(2), 79-84. Abstract.

Troosters T, Celli B, Lystig T, Kesten S, Mehra S, Tashkin DP, Decramer M (2010). Tiotropium as a first maintenance drug in COPD: secondary analysis of the UPLIFT(R) trial. European Respiratory Journal, 36(1), 65-73.

Small N, Gardiner C, Barnes S, Gott M, Payne S, Seamark D, Halpin D (2010). Using a prediction of death in the next 12 months as a prompt for referral to palliative care acts to the detriment of patients with heart failure and chronic obstructive pulmonary disease. Palliat Med, 24(7), 740-741. Author URL.

Gott M, Gardiner C, Small N, Payne S, Seamark D, Barnes S, Halpin D, Ruse C (2009). Barriers to advance care planning in chronic obstructive pulmonary disease. Palliat Med, 23(7), 642-648. Abstract. Author URL.

Halpin DMG, Tashkin DP (2009). Defining disease modification in chronic obstructive pulmonary disease. COPD: Journal of Chronic Obstructive Pulmonary Disease, 6(3), 211-225. Abstract.

Decramer M, Celli B, Kesten S, Lystig T, Mehra S, Tashkin DP (2009). Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. The Lancet, 374(9696), 1171-1178.

Hyland ME, Blake S, Greaves CJ, Pinnuck M, Seamark C, Seamark D, Ward D, Halpin DMG (2009). Guidelines versus practice: UK asthma nurses often recommend intermittent, symptom-driven use of inhaled corticosteroids. Prim Care Respir J, 18(2), 114-117. Abstract. Author URL.

Gardiner C, Gott M, Small N, Payne S, Seamark D, Barnes S, Halpin D, Ruse C (2009). Living with advanced chronic obstructive pulmonary disease: patients concerns regarding death and dying. Palliat Med, 23(8), 691-697. Abstract. Author URL.

Halpin D, Menjoge S, Viel K (2009). Patient-level pooled analysis of the effect of tiotropium on COPD exacerbations and related hospitalisations. Prim Care Respir J, 18(2), 106-113. Abstract. Author URL.

Halpin DMG (2009). Preventing chronic obstructive pulmonary disease. Expert Review of Respiratory Medicine, 3(5), 449-452.

Bryden C, Bird W, Titley HA, Halpin DMG, Levy ML (2009). Stratification of COPD patients by previous admission for targeting of preventative care. RESPIRATORY MEDICINE, 103(4), 558-565. Author URL.

Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, Decramer M (2008). A 4-Year Trial of Tiotropium in Chronic Obstructive Pulmonary Disease. New England Journal of Medicine, 359(15), 1543-1554.

Halpin DMG (2008). ABCD of the phosphodiesterase family: Interaction and differential activity in COPD. International Journal of COPD, 3(4), 543-561. Abstract.

Price L, Kassianos G, Brown MJ, Gaw A, Kirby M, Morrell J, Schachter M, Tamargo J, Yawn B, Yawn R, et al (2008). Aliskiren - the first of a new class of antihypertensive. Drugs in Context, 4(1), 105-120. Abstract.

Chambers S, Kassianos G, Brown P, Gaw A, Kirby M, Morrell J, Schachter M, Tamargo J, Yawn B, Yawn R, et al (2008). Cervarix - Preventing cervical cancer and other diseases related to HPV. Drugs in Context, 4(1), 59-70. Abstract.

Halpin DMG (2008). Community care for COPD: the good, the bad and the ugly. THORAX, 63(3), 187-189. Author URL.

Croom K, Kassianos G, Schachter M, Morrell J, Gaw A, Kirby M, Tamargo J, Yawn B, Yawn R, Barakat K, et al (2008). Coversyl Plus - Treating hypertension and improving clinical outcomes in T2D and other high risk groups. Drugs in Context, 4(1), 71-84. Abstract.

Halpin DMG, Seamark CJ, Seamark DA (2008). End-of-life care for patients with COPD in the community setting. BRITISH JOURNAL OF GENERAL PRACTICE, 58(551), 390-392. Author URL.

Croom K, Kassianos G, Gaw A, Kirby M, Morrell J, Schachler M, Tamargo J, Yawn B, Yawn R, Barakal K, et al (2008). Ezetimibe - a clinically effective and a cost-effective treatment option for dyslipidaemia. Drugs in Context, 4(1), 85-104. Abstract.

Chambers S, Kassianos G, Brown P, Gaw A, Kirby M, Morrell J, Schachter M, Tamargo J, Yawn B, Yawn R, et al (2008). Gardasil - Preventing cervical cancer and other diseases related to HPV. Drugs in Context, 4(1), 29-40. Abstract.

Crowe E, Halpin D, Stevens P (2008). Guidelines - Early identification and management of chronic kidney disease: summary of NICE guidance. BMJ-BRITISH MEDICAL JOURNAL, 337(7673). Author URL.

Halpin DMG, Peterson S, Larsson TP, Calverley PMA (2008). Identifying COPD patients at increased risk of mortality: Predictive value of clinical study baseline data. Respiratory Medicine, 102(11), 1615-1624. Abstract.

Croom K, Kassianos G, Schachter M, Morrell J, Gaw A, Kirby M, Tamargo J, Yawn B, Yawn R, Barakat K, et al (2008). Inegy - Effective combination treatment to target LDL-C levels. Drugs in Context, 4(1), 41-58. Abstract.

Halpin D (2008). Mortality in COPD: Inevitable or Preventable? Insights from the Cardiovascular Arena. COPD-JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 5(3), 187-200. Author URL.

Halpin DMG (2008). Symbicort: a pharmacoeconomic review. Journal of Medical Economics, 11(2), 345-362. Abstract.

Chambers S, Schachter M, Morrell J, Kassianos G, Gaw A, Kirby M, Tamargo J, Yawn B, Yawn R, Barakat K, et al (2008). Telmisartan - an effective antihypertensive for 24-hour blood pressure control. Drugs in Context, 4(1), 1-14. Abstract.

Chambers S, Schachter M, Price D, Kassianos G, Gaw A, Kirby M, Morrell J, Tamargo J, Yawn B, Yawn R, et al (2008). Tiotropium - Advancing the treatment of COPD. Drugs in Context, 4(1), 15-28. Abstract.

Halpin DMG (2008). Uplifting times for COPD. Primary Care Respiratory Journal, 17(4), 197-198.

Halpin DMG, O'Reilly JF, Connellan S, Rudolf M (2007). Confidence and understanding among general practitioners and practice nurses in the UK about diagnosis and management of COPD. RESPIRATORY MEDICINE, 101(11), 2378-2385. Author URL.

Halpin DMG (2007). Management of exacerbations of chronic obstructive pulmonary disease. Minerva Pneumologica, 46(1), 5-17. Abstract.

Seamark DA, Seamark CJ, Halpin DMG (2007). Palliative care in chronic obstructive pulmonary disease: a review for clinicians. JOURNAL OF THE ROYAL SOCIETY OF MEDICINE, 100(5), 225-233. Author URL.

Halpin DM (2007). Systemic effects of chronic obstructive pulmonary disease. Expert Review of Respiratory Medicine, 1(1), 75-84. Abstract.

Halpin DMG (2006). Assessing the severity of COPD. Primary Care Respiratory Journal, 15(2), 78-80.

Halpin DMG (2006). Chronic obstructive pulmonary disease, inflammation and PDE4 inhibitors. BRITISH JOURNAL OF HOSPITAL MEDICINE, 67(7), 370-374. Author URL.

Halpin DMG (2006). Diagnosing COPD. International journal of chronic obstructive pulmonary disease, 1(4), 343-344.

Halpin D (2006). Editorial. Drugs in Context, 2(6), 231-232.

Dyer MJ, Halpin DMG, Stein K (2006). Inhaled ciclesonide versus inhaled budesonide or inhaled beclomethasone or inhaled fluticasone for chronic asthma in adults: a systematic review. BMC Fam Pract, 7 Abstract. Author URL.

Halpin DMG (2006). The diagnosis and management of COPD in older people. CME Journal Geriatric Medicine, 8(1), 11-17. Abstract.

(2005). Beta2 agonist reversibility testing in COPD diagnosis. Drug and Therapeutics Bulletin, 43(12), 89-91.

Halpin DMG (2005). Evaluating the effectiveness of combination therapy to prevent COPD exacerbations: the value of NNT analysis. International Journal of Clinical Practice, 59(10), 1187-1194. Abstract.

Halpin DMG (2005). NICE versus nGMS: What the evidence tells us. Primary Care Respiratory Journal, 14(1), 8-10.

Greaves CJ, Hyland ME, Halpin DMG, Blake S, Seamark D (2005). Patterns of corticosteroid medication use: non-adherence can be effective in milder asthma. Prim Care Respir J, 14(2), 99-105. Abstract. Author URL.

Pearson M (2004). Chronic Obstructive Pulmonary Disease: National clinical guideline on management of chronic obstructive pulmonary disease in adults in primary and secondary care. Thorax, 59(SUPPL. 1), 1-232.

Ward DG, Halpin DMG, Seamark DA (2004). How accurate is a diagnosis of asthma in a general practice database? a review of patients' notes and questionnaire-reported symptoms. British Journal of General Practice, 54(507), 753-758. Abstract.

Seamark DA, Blake SD, Seamark CJ, Halpin DMG (2004). Living with severe chronic obstructive pulmonary disease (COPD): Perceptions of patients and their carers. An interpretative phenomenological analysis. Palliative Medicine, 18(7), 619-625. Abstract.

Halpin D (2004). NICE guidance for COPD. Thorax, 59(3), 181-182. Author URL.

Celli B, Halpin D, Hepburn R, Byrne N, Keating ET, Goldman M (2003). Symptoms are an important outcome in chronic obstructive pulmonary disease clinical trials: results of a 3-month comparative study using the Breathlessness, Cough and Sputum Scale (BCSS). Respir Med, 97 Suppl A, S35-S43. Abstract. Author URL.

Greaves CJ, Eiser C, Seamark D, Halpin DMG (2002). Attack context: an important mediator of the relationship between psychological status and asthma outcomes. Thorax, 57(3), 217-221. Abstract. Author URL.

Ward JA, Akers G, Ward DG, Pinnuck M, Williams S, Trott J, Halpin DMG (2002). Feasibility and effectiveness of a pulmonary rehabilitation programme in a community hospital setting. British Journal of General Practice, 52(480), 539-542. Abstract.

Sweeney KG, Edwards K, Stead J, Halpin D (2001). A comparison of professionals' and patients' understanding of asthma: Evidence of emerging dualities?. Medical Humanities, 27(1), 20-25. Abstract.

Seamark DA, Williams S, Timon S, Ward A, Ward D, Seamark C, Pinnuck M, Powell R, Halpin D (2001). Home or surgery based screening for chronic obstructive pulmonary disease (COPD)?. Primary Care Respiratory Journal, 10(2), 30-33. Abstract.

Halpin D (2001). Managing pneumonia in general practice. Practitioner, 245(1619), 108-115. Author URL.

(2001). Managing stable chronic obstructive pulmonary disease. Drug and Therapeutics Bulletin, 39(11), 81-85.

Furness J, Fearby S, Clough JB, Clark CE, Coote JM, Silver DAT, Halpin DMG (2000). Asthma after childhood pneumonia. BMJ, 321(7271).

Clark CE, Coote JM, Silver DAT, Halpin DMG (2000). Asthma after childhood pneumonia - Reply. BRITISH MEDICAL JOURNAL, 321(7271), 1290-1290. Author URL.

Furness J, Fearby S, Clough JB, Clark CE, Coote JM, Silver DAT, Halpin DMG (2000). Asthma after childhood pneumonia [7] (multiple letters). British Medical Journal, 321(7271), 1289-1290.

Clark CE, Coote JM, Silver DAT, Halpin DMG (2000). Asthma after childhood pneumonia: six year follow up study. BRITISH MEDICAL JOURNAL, 320(7248), 1514-1516. Author URL.

Connolly KC, Peake MD, Halpin DMG, Golightly L, Turbitt ML (2000). Challenging current asthma treatment guidelines: Improved control of asthma symptoms with nebulised budesonide in patients with severe asthma receiving continuous oral steroids. Disease Management and Health Outcomes, 7(4), 217-225. Abstract.

Halpin DMG, Hart E, Harris T, Harbour R, Rudolf M (2000). What do general practice records tell us about the current management of COPD and the impact of the BTS COPD guidelines?. Thorax, 55(SUPPL. 3). Abstract.

Halpin DMG, Williams S, Timon S, Ward AW, Ward DW, Seamark CJ, Pinnuck M, Seamark DA (1999). Home or surgery based screening for COPD?. Thorax, 54(SUPPL. 3). Abstract.

Forsling ML, Montgomery H, Halpin D, Windle RJ, Treacher DF (1998). Daily patterns of secretion of neurohypophysial hormones in man: effect of age. Exp Physiol, 83(3), 409-418. Abstract. Author URL.

Bramwell EC, Halpin DMG, Duncan‐Skingle F, Hodson ME, Geddes DM (1995). Home treatment of patients with cystic fibrosis using the‘Intermate’: the first year's experience. Journal of Advanced Nursing, 22(6), 1063-1067. Abstract.

Halpin DMG, Graneek BJ, Turner-Warwick M, Taylor AJN (1994). Extrinsic allergic alveolitis and asthma in a sawmill worker: Case report and review of the literature. Occupational and Environmental Medicine, 51(3), 160-164. Abstract.

Halpin DMG, Graneek BJ, Lacey J, Nieuwenhuijsen MJ, Williamson PAM, Venables KM, Taylor AJN (1994). Respiratory symptoms, immunological responses, and aeroallergen concentrations at a sawmill. Occupational and Environmental Medicine, 51(3), 165-172. Abstract.

Halpin DMG, Hodson ME, Geddes DM (1992). Sex of children born to women with cystic fibrosis. The Lancet, 339(8799).

Sorrell M, Halpin DMG (1991). Art and neurology. The British Journal of Aesthetics, 31(3), 241-250.

Halpin DMG, Burrin JM, Joplin GF (1990). Serum testosterone levels in women with Cushing's disease. Acta Endocrinologica, 122(1), 71-75. Abstract.

Halpin DM, Trend P, Symon L, Harding AE (1990). Type 1 Arnold-Chiari malformation in a 77 year old woman. J Neurol Neurosurg Psychiatry, 53(1), 88-89. Author URL.

Halpin D, Wessely S (1989). VP-1 antigen in chronic postviral fatigue syndrome. Lancet, 1(8645), 1028-1029. Author URL.

Halpin DMG, Charlton HM (1988). Effects of short-term injection of gonadotrophins on ovarian follicle development in hypogonadal (hpg) mice. Journal of Reproduction and Fertility, 82(1), 393-400. Abstract.

Higgins JRA, Halpin DMG, Midgley AK (1988). Tension pneumoperitoneum: a surgical emergency. British Journal of Hospital Medicine, 39(2), 160-161.

Higgins JRA, Halpin DMG, Kapff PD (1987). Penetrating injury on an artificial ski slope. Injury, 18(5), 342-343.

Halpin DMG, Charlton HM, Faddy MJ (1986). Effects of gonadotrophin deficiency on follicular development in hypogonadal (hpg) mice. Journal of Reproduction and Fertility, 78(1), 119-125.

Halpin DMG, Jones A, Fink G, Charlton HM (1986). Postnatal ovarian follicle development in hypogonadal (hpg) and normal mice and associated changes in the hypothalamic-pituitary ovarian axis. Journal of Reproduction and Fertility, 77(1), 287-296.

Hume DA, Halpin D, Charlton H, Gordon S (1984). The mononuclear phagocyte system of the mouse defined by immunohistochemical localization of antigen F4/80: macrophages of endocrine organs. Proc Natl Acad Sci U S A, 81(13), 4174-4177. Abstract. Author URL.

Charlton HM, Speight A, Halpin DMG, Bramwell A, Sheward WJ, Fink G (1983). Prolactin measurements in normal and hypogonadal (hpg) mice: Developmental and experimental studies. Endocrinology, 113(2), 545-548. Abstract.

Charlton HM, Halpin DMG, Iddon C, Rosie R, Levy G, McDowell IFW, Megson A, Morris JF, Bramwell A, Speight A, et al (1983). The effects of daily administration of single and multiple injections of gonadotropin-releasing hormone on pituitary and gonadal function in the hypogonadal (hpg) mouse. Endocrinology, 113(2), 535-544. Abstract.

Charlton HM, Parry D, Halpin DMG, Webb R (1982). Distribution of 125I-labelled follicle-stimulating hormone and human chorionic gonadotrophin in the gonads of hypogonadal (hpg) mice. Journal of Endocrinology, 93(2), 247-252. Abstract.

Charlton HM, Fink G, Halpin DMG (1981). The effects of multiple injections of gonadotrophin-releasing hormone (GnRH) in the hypogonadal mouse. Journal of Physiology, Vol.320

Chapters

Halpin DMG (2024). Defining COPD in the 21st century. In (Ed) COPD in the 21st Century, European Respiratory Society (ERS), 30-44.

Halpin DMG, Dekhuijzen PNR (2023). Selection of Inhaler Delivery System for Adult Outpatients. In (Ed) Inhaled Delivery Systems for the Treatment of Asthma and COPD, Taylor & Francis, 120-134.

Halpin DMG (2022). Clinical Features and Diagnosis of COPD. In (Ed) Encyclopedia of Respiratory Medicine, Elsevier, 621-630.

Halpin D, Cooper C, Leach R (2014). Chronic Obstructive Pulmonary Disease. In (Ed) Oxford Desk Reference: Acute Medicine, Oxford University Press. Abstract.

Halpin D (2011). COPD. In (Ed) Advanced Respiratory Critical Care, Oxford University Press. Abstract.

Halpin D, Bakere H (2011). Pneumonia. In (Ed) Advanced Respiratory Critical Care, Oxford University Press. Abstract.

Halpin D (2009). COPD pathophysiology. In (Ed) Oxford Desk Reference: Respiratory Medicine, Oxford University Press. Abstract.

Halpin DMG, Seamark DA, Seamark CJ (2009). Palliative and end-of-life care for patients with respiratory disease. In (Ed) Respiratory Diseases in the Elderly, European Respiratory Society (ERS), 327-353.

Halpin D (2001). Chronic Obstructive Pulmonary Disease. In (Ed) Respiratory Medicine, CRC Press. Abstract.

Halpin D, Geddes D (1994). Rheumatoid arthritis and connective tissue associated obliterative bronchiolitis. In (Ed) Diseases of the Bronchioles, Lippincott Williams & Wilkins.

Halpin D (1992). Blood glucose homeostasis. In (Ed) PHYSIOLOGY SURGICAL PRACTICE, CRC Press. Abstract.

Halpin D (1992). Puberty, the menstrual cycle and the menopause. In (Ed) PHYSIOLOGY SURGICAL PRACTICE, CRC Press. Abstract.

Halpin D (1992). Tests of endocrine function. In (Ed) PHYSIOLOGY SURGICAL PRACTICE, CRC Press. Abstract.

Halpin D, Collins JV (1990). Bronchoscopy. In (Ed) Respiratory Medicine, W.B. Saunders Company. Abstract.

Conferences

Domingo C, Lommatzsch M, Hanania N, Canonica G, Halpin D, Lugogo N, Rhee C, Altincatal A, Pandit-Abid N, Nash S, et al (2024). Association of Baseline Lung Function and Likelihood of Oral Corticosteroid Reduction in Patients with OCS-Dependent Severe Asthma. 64. Kongress der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin e. V.

Domingo C, Hanania N, Canonica G, Halpin D, Lugogo N, Rhee C, Nash S, Pandit-Abid N (2023). ASSOCIATION BETWEEN BASELINE CHARACTERISTICS AND ORAL CORTICOSTEROID REDUCTION IN PATIENTS WITH ORAL CORTICOSTEROID-DEPENDENT SEVERE ASTHMA. Author URL.

Maspero JF, Corren J, Katelaris C, Castro M, Humbert MJC, Halpin DMG, Altincatal A, Pandit-Abid N, Soler X, Radwan A, et al (2023). Dupilumab Reduced Severe Exacerbation Rates and Improved Pre-bronchodilator Fev 1 in Patients with Moderate-to-Severe Asthma Regardless of Exacerbation History of 蠅1, 蠅2, or 蠅3 Prior Exacerbations: Liberty Asthma Traverse. C31. BIOLOGICS WANT TO RULE THE (ASTHMA) WORLD.

Rhee CK, Corren J, Castro M, Maspero JF, Humbert M, Halpin DMG, Altincatal A, Pandit-Abid N, Soler X, Siddiqui S, et al (2023). Dupilumab improved lung function and reduced exacerbation rates in patients with moderate-tosevere asthma and prior exacerbations: LIBERTY ASTHMA TRAVERSE study. Author URL.

Ismaila A, Haeussler K, Czira A, Youn J, Malmenäs M, Risebrough N, Nassim M, Sharma R, Compton C, Vogelmeier C, et al (2023). Netzwerk-Metaanalyse (NMA) der Wirksamkeit von Fluticasonfuroat/Umeclidinium/Vilanterol (FF/UMEC/VI) im Vergleich zu anderen Tripel-Therapien zur Behandlung der chronisch obstruktiven Lungenerkrankung (COPD): ein Vergleich der annualisierten Raten an moderaten und schweren Exazerbationen. 63. Kongress der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin e. V.

Dickens A, Halpin D, Carter V, Skinner D, Beeh K, Chalmers J, Clark A, Hannan N, Kaplan A, Kostikas K, et al (2023). P237 Technophobia is not the most significant patient-reported barrier to accepting a digital adherence package: an analysis of the MAGNIFY trial. ‘Call me maybe’ – Virtual management of respiratory disease.

Ismaila AS, Haeussler K, Czira A, Youn J, Malmenas M, Risebrough N, Agarwal J, Nassim M, Sharma R, Compton C, et al (2022). Comparative Efficacy of Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Versus Other Triple Therapies for the Treatment of Chronic Obstructive Pulmonary Disease (COPD): a Systematic Literature Review and Network Meta-Analysis. Author URL.

Corren J, Castro M, Maspero JF, Humbert M, Halpin DMG, Altincatal A, Pandit-Abid N, Soler X, Siddiqui S, Jacob-Nara JA, et al (2022). Dupilumab improved lung function and reduces exacerbations in patients with 1, 2, or 3 prior exacerbations: TRAVERSE. 05.01 - Airway pharmacology and treatment.

Cai R, Martin A, Ge Y, Risebrough N, Sharma R, Haeussler K, Compton C, Halpin D, Ismaila AS (2022). ECONOMIC ANALYSIS OF NEW SINGLE-INHALER TRIPLE THERAPIES IN PATIENTS WITH COPD IN THE UK. Author URL.

Ismaila AS, Haeussler K, Czira A, Youn J, Malmenas M, Risebrough N, Agarwal J, Nassim M, Sharma R, Compton C, et al (2022). Network Meta-Analysis of the Efficacy of Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Versus Other Triple Therapies for the Treatment of Chronic Obstructive Pulmonary Disease (COPD): a Comparison of Annual Moderate and Severe Exacerbations. Author URL.

Dickens A, Halpin D, Carter V, Skinner D, Beeh K, Chalmers J, Clark A, Hannan N, Kaplan A, Kostikas K, et al (2022). P186 Facilitators to recruiting COPD patients to an adherence intervention trial. ‘Catch Me If you Can’ – Opportunities to improve care in airways disease.

Dickens A, Halpin D, Carter V, Skinner D, Beeh K, Chalmers J, Clark A, Hannan N, Kaplan A, Kostikas K, et al (2022). Patient-reported barriers to accepting a technological adherence package in the MAGNIFY trial. 01.03 - General practice and primary care.

Dickens A, Halpin D, Carter V, Skinner D, Beeh K, Chalmers J, Clark A, Hannan N, Kaplan A, Kostikas K, et al (2022). S117 Poor adherence in exacerbating COPD patients: magnitude and related factors at baseline in the MAGNIFY pragmatic trial. ‘Home Alone’ – Remote monitoring in lung disease.

Stolbrink M, Thomson H, Hadfield RM, Ozoh OB, Nantanda R, Jayasooria S, Allwood B, Halpin DM, Salvi S, Montes De Oca M, et al (2022). The availability, cost and affordability of essential medicines for asthma and COPD in low- and middle-income countries: a systematic review. 05.01 - Airway pharmacology and treatment.

Halpin DMG, Rothnie KJ, Banks V, Czira A, Compton C, Wood R, Tritton T, Massey O, Wild R, Snowise N, et al (2021). ARE PATIENTS WITH COPD MORE ADHERENT TO FLUTICASONE FUROATE/UMECLIDINIUM/VILANTEROL (FF/UMEC/VI) COMPARED WITH MULTIPLE-INHALER TRIPLE THERAPY IN a REAL-WORLD UK PRIMARY CARE TREATED POPULATION?. Author URL.

Bourdin A, Virchow J, Papi A, Lugogo N, Halpin D, Daizadeh N, Ortiz B, Djandji M (2021). DUPILUMAB EFFICACY IN PATIENTS WITH TYPE 2 ASTHMA WITH/WITHOUT ALLERGIC PHENOTYPE RECEIVING HIGH-DOSE INHALED CORTICOSTEROIDS. Author URL.

Ribas CD, Maspero J, Castro M, Hanania N, Ford L, Halpin D, Jackson D, Daizadeh N, Djandji M, Mitchell C, et al (2021). DUPILUMAB REDUCED ORAL CORTICOSTEROID USE AND IMPROVED CLINICAL OUTCOMES REGARDLESS OF BASELINE OCS DOSE IN PATIENTS WITH UNCONTROLLED, SEVERE ASTHMA IN THE LIBERTY ASTHMA VENTURE STUDY. Author URL.

Thompson P, Criner G, Halpin D, Halpin M, Jones C, Kilbride S, Lipson D, Maghzal G, Martinez F, Singh D, et al (2021). EFFECT OF CHRONIC MUCUS HYPERSECRETION ON COPD OUTCOMES: IMPACT TRIAL. Author URL.

Bratton D, Hartley B, Barnes N, Brusselle G, Compton C, Corbridge T, Dransfield M, Halpin D, Han M, Jones CE, et al (2020). BENEFIT-RISK PROFILES OF FLUTICASONE FUROATE/UMECLIDINIUM/VILANTEROL (FF/UMEC/VI) VS UMEC/VI IN PATIENTS WITH COPD: a MARKOV MODEL. Author URL.

Criner G, Barnes N, Brusselle G, Compton C, Dransfield M, Halpin D, Lan M, Christine H, Jones E, Kaye M, et al (2020). DEMOGRAPHIC AND CLINICAL CHARACTERISTICS OF PATIENTS EXPERIENCING ON-TREATMENT EXACERBATIONS, ON-TREATMENT DEATH, OR PREMATURE STUDY TREATMENT WITHDRAWAL: THE IMPACT TRIAL. Author URL.

Halpin D, Korn S, Matucci A, Bourdin A, Daizadeh N, Ortiz B, Djandji M, Deniz Y, Rowe P (2020). EFFICACY OF DUPILUMAB IN PATIENTS WITH ASTHMA WITH/WITHOUT SUBSTANTIAL REDUCTION IN FRACTIONAL EXHALED NITRIC OXIDE. Author URL.

Maspero JF, Halpin DMG, Jackson D, Hanania NA, Castro M, Domingo C, Daizadeh N, Djandji M, Rowe P, Deniz Y, et al (2020). Effect of dupilumab on oral corticosteroid use in severe asthma patients with improving lung function. Author URL.

Compton C, Worsley S, Midwinter D, Ismaila A, Beeh K-M, Di Boscio V, Kocks J, Marin JM, Tabberer M, Snowise NG, et al (2020). INTREPID study: Once-daily single-inhaler fluticasone furoate/umeclidinium/vilanterol vs multiple-inhaler triple therapy; sub-analysis by prior medication strata. Author URL.

Halpin DM, Worsley S, Ismaila AS, Astrom J, Beeh KM, Brintziki D, Di Boscio V, Kocks J, Marin JM, Tabberer M, et al (2020). Intrepid: Clinical Effectiveness of Once-Daily Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol Versus Multiple-Inhaler Triple Therapy in Usual Clinical Practice. Author URL.

Calverley P, Celli B, Crim C, Dransfield M, Halpin D, Han ML, Jones CE, Kilbride S, Lange P, Lettis S, et al (2020). RISK OF DEATH AND COPD HOSPITALIZATION WITH FLUTICASONE FUROATE-CONTAINING THERAPY: POST HOC SUBGROUP ANALYSIS FROM THE SUMMIT TRIAL IN PATIENTS WITH COPD AND a HISTORY OF EXACERBATION. Author URL.

Dransfield M, Halpin D, Han ML, Hartley B, Jones CE, Kalhan R, Kilbride S, Kunisaki K, Lange P, Lipson D, et al (2020). TIME-DEPENDENT RISK OF CARDIOVASCULAR EVENTS FOLLOWING AN EXACERBATION IN PATIENTS WITH COPD: POST HOC ANALYSIS FROM THE IMPACT TRIALl. Author URL.

Han M, Criner G, Dransfield M, Halpin D, Jones C, Kilbride S, Lange P, Lomas D, Martinez F, Quasny H, et al (2020). The IMPACT Trail: Single Inhaler Triple Therapy vs. dual therapies: Consistent benefit across multiple exacerbation endpoints. 61. Kongress der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin e.V.

Bafadhel M, Barnes N, Bourke S, Compton C, Criner G, Dransfield M, Halpin D, Han M, Hartley B, Jones CE, et al (2019). Analysis of IMPACT: is one blood eosinophil count measurement sufficient to predict ICS treatment response in COPD?. Author URL.

Hanania N, Wise R, Feldman G, Siler T, Halpin D, Han M, Lipson D, Kilbride S, Jones CE, Shostak L, et al (2019). COMPARISON BETWEEN FF/UMEC/VI VS UMEC/VI AND FF/VI AND UMEC/VI VS FF/VI BASED ON BASELINE EXACERBATION HISTORY AND FEV1: SUB-ANALYSIS FROM THE IMPACT TRIAL. Author URL.

Stiegler MA, Thomashow B, Criner GJ, Dransfield MT, Halpin DMG, Han MK, Jones CE, Kilbride S, Lange P, Lomas DA, et al (2019). COPD Assessment Test (CAT) Score is Associated with Risk of Future Exacerbation: an Analysis from the IMPACT Trial. Author URL.

Kerkhof M, Chaudhry I, Kocks J, Pavord I, Halpin D, Usmani O, Morris T, Alacqua M, Price D (2019). Disease Severity of Patients with High Blood Eosinophil Counts Treated for COPD Exacerbation with or Without Oral Corticosteroids. Author URL.

Hanania N, Mannino D, Criner G, Dransfield M, Han M, Jones CE, Kilbride S, Lomas D, Martinez F, Singh D, et al (2019). EFFECT OF AGE ON EFFICACY AND SAFETY OF ONCE-DAILY SINGLE-INHALER TRIPLE THERAPY FLUTICASONE FUROATE/UMECLIDINIUM/VILANTEROL IN PATIENTS WITH COPD: a POST-HOC ANALYSIS OF THE IMPACT TRIAL. Author URL.

Kerkhof M, Chaudhry I, Kocks J, Pavord I, Halpin D, Usmani O, Morris T, Alacqua M, Price D (2019). Eosinophil Counts as a Biomarker of Oral Corticosteroid Treatment Success for Patients with COPD. Author URL.

Singh D, Criner GJ, Dransfield MT, Halpin DMG, Han MK, Jones CE, Kilbride S, Lange P, Lomas DA, Martinez FJ, et al (2019). InforMing the PAthway of COPD Treatment (The IMPACT Study): Single Inhaler Triple Therapy (Fluticasone Furoate/Umeclidinium/Vilanterol) Versus Fluticasone Furoate/Vilanterol and Umeclidinium/Vilanterol in Patients with COPD: an Analysis Based on Baseline COPD Medication Use. Author URL.

Han MK, Criner GJ, Dransfield MT, Halpin DMG, Jones CE, Kilbride S, Lange P, Lipson DA, Lomas DA, Martinez FJ, et al (2019). Preventing Clinically Important Deterioration (CID) of COPD with Single-inhaler Triple Therapy Fluticasone Furoate/Umeclidinium/Vilanterol: a Prospective Analysis of the IMPACT Trial. Author URL.

Lipson DA, Criner G, Dransfield MT, Halpin DMG, Han MK, Jones CE, Kilbride S, Lange P, Lomas DA, Martinez FJ, et al (2019). The IMPACT Trial: Single Inhaler Triple Therapy Fluticasone Furoate/Umeclidinium/Vilanterol Versus Fluticasone Furoate/Vilanterol and Umeclidinium/Vilanterol in Patients with COPD: Results on Cardiovascular Safety. Author URL.

Kaisermann MC, Criner GJ, Dransfield MT, Halpin DM, Han MK, Jones CE, Kilbride S, Lange P, Lomas DA, Martinez FJ, et al (2019). The IMPACT Trial: Single Inhaler Triple Therapy Fluticasone Furoate/Umeclidinium/Vilanterol Versus Fluticasone Furoate/Vilanterol and Umeclidinium/Vilanterol in Patients with COPD: Results on Rescue Use and Night-Time Awakenings. Author URL.

Criner GJ, Dransfield M, Halpin DMG, Han MK, Jones CE, Kilbride S, Lange P, Lomas DA, Martinez F, Pascoe S, et al (2019). The IMPACT Trial: Single Inhaler Triple Therapy Fluticasone Furoate/Umeclidinium/Vilanterol versus Fluticasone Furoate/Vilanterol and Umeclidinium/Vilanterol in Patients with COPD: a Pre-Specified Analysis of Safety According to Age. Author URL.

Halpin DMG, Bardsley S, Criner G, Dransfield M, Han MK, Jones CE, Kilbride S, Lomas DA, Martinez F, Pascoe S, et al (2019). The IMPACT Trial: Single Inhaler Triple Therapy fluticasone Furoate/Umeclidinium/Vilanterol Versus Fluticasone Furoate/Vilanterol and Umeclidinium/Vilanterol in Patients with COPD: Analysis According to Smoking Status. Author URL.

Han MK, Criner G, Dransfield M, Halpin D, Jones CE, Kilbride S, Lange P, Lomas D, Martinez F, Quasny H, et al (2019). The IMPACT Trial: Single Inhaler Triple Therapy vs dual therapies: Consistent benefit across multiple exacerbation endpoints. Author URL.

Lipson DA, Criner G, Dransfield M, Halpin D, Han M, Jones CE, Kilbride S, Lange P, Lomas D, Martinez F, et al (2019). The IMPACT Trial: Single Inhaler Triple Therapy vs dual therapies: Efficacy across multiple COPD endpoints over time. Author URL.

Han MK, Halpin DM, Martinez FJ, Miravitlles M, Singh D, de la Hoz A, Voss F, Rabe F (2018). A Composite Endpoint of Clinically Important Deterioration in Chronic Obstructive Pulmonary Disease and its Association with Increased Mortality: a Post Hoc Analysis of the UPLIFT Study. Author URL.

Halpin DMG, de Jong H, Carter V, Skinner D, Price D (2018). CHARACTERISTICS OF ESTABLISHED AND NEWLY TREATED PATIENTS WITH COPD ACCORDING TO GOLD 2017 IN a UK PRIMARY CARE POPULATION. Author URL.

Halpin D, Hamelmann E, Moroni-Zentgraf P, Van Hecke B, Unseld A, Kerstjens H (2018). COMPARATIVE RESPONSES IN LUNG FUNCTION MEASUREMENTS IN MODERATE SYMPTOMATIC ASTHMA. Author URL.

Lipson DA, Barnhart F, Boucot I, Crim C, Brealey N, Criner GJ, Dransfield M, Halpin DMG, Kilbride S, Han MK, et al (2018). Comparison of LAMA/LABA vs ICS/LABA in high risk COPD patients: Pre-specified analysis on lung function and health status from the IMPACT trial. Author URL.

Halpin D, Vogelmeier CF, Mackay AJ, Mezzi K, Goyal P, Gupta P, Kostikas K, Wedzicha JA (2018). Efficacy of indacaterol/glycopyrronium versus salmeterol/fluticasone in current and ex-smokers: a pooled analysis of IGNITE trials. Author URL.

Lipson DA, Barnhart F, Boucot I, Crim C, Brealey N, Criner GJ, Dransfield M, Halpin DMG, Kilbride S, Han MK, et al (2018). Exacerbation outcomes with LAMA/LABA and ICS/LABA in high risk COPD patients in the IMPACT trial. Author URL.

Singh D, Barnhart F, Brealey N, Criner G, Dransfield M, Halpin DMG, Han MK, Jones CE, Kilbride S, Lange P, et al (2018). FF/UMEC/VI versus FF/VI and UMEC/VI in the ELLIPTA device in patients with COPD: Subgroup analyses from the IMPACT trial. Author URL.

Frith P, Halpin D, Moroni-Zentgraf P, van Hecke B, Sigmund R, Kerstjens H (2018). FVC RESPONSE TO TIOTROPIUM RESPIMAT® IN ADULTS WITH SYMPTOMATIC ASTHMA. Author URL.

Singh D, Criner G, Day NC, Dransfield M, Halpin DMG, Han MK, Jones CE, Kilbride S, Lange P, Lipson DA, et al (2018). Late Breaking Abstract - Analysis of the InforMing the PAthway of COPD Treatment (IMPACT) study in the subgroup of patients taking triple therapy at screening. Author URL.

Pascoe S, Barnes N, Brusselle G, Compton C, Criner G, Dransfield M, Halpin DMG, Han MK, Hartley B, Hilton E, et al (2018). Late Breaking Abstract - Blood eosinophil counts and treatment response in COPD: analyses of IMPACT. Author URL.

Halpin DMG, De Jong H, Carter V, Skinner D, Price D (2018). Prevalence of comorbidities in established and newly treated patients with COPD according to GOLD 2017 in a UK primary care population. Author URL.

Dransfield M, Crim C, Criner G, Halpin DMG, Han MK, Jones CE, Kilbride S, Lange P, Lipson DA, Lomas DA, et al (2018). RISK OF EXACERBATION AND PNEUMONIA WITH SINGLE INHALER TRIPLE VERSUS DUAL THERAPY IN IMPACT. Author URL.

Lipson DA, Barnhart F, Brealey N, Day NC, Brooks J, Criner G, Dransfield MT, Halpin DM, Han MK, Jones C, et al (2018). Reduction in All-Cause Mortality with Single Inhaler Triple Therapy (FF/UMEC/VI) Versus Dual Therapy (FF/VI and UMEC/VI) in Symptomatic Patients with COPD: Prespecified Analysis of the Phase III IMPACT Trial. Author URL.

Dransfield M, Crim C, Criner G, Halpin D, Han M, Jones CE, Kilbride S, Lange P, Lipson D, Lomas D, et al (2018). Risk of exacerbation and pneumonia with single inhaler triple versus dual therapy in IMPACT. Author URL.

Lipson DA, Barnhart F, Brealey N, Day NC, Brooks J, Criner G, Dransfield MT, Halpin DM, Han MK, Jones C, et al (2018). Single Inhaler Triple-Therapy (ICS/LAMA/LABA) Versus Dual-Therapy (ICS/LABA or LAMA/LABA) in Patients with COPD at Risk of Exacerbations: Efficacy and Safety Results of the Phase III IMPACT Trial. Author URL.

Dransfield M, Halpin D, Barnacle H, Mohrlang C, Birk R, Brealey N, Zhu C-Q, Lipson D (2018). Single inhaler triple therapy in patients with advanced COPD (FULFIL): exacerbation/pneumonia composite outcomes. Author URL.

FitzGerald JM, Buhl R, Casale TB, Engel M, Sigmund R, Halpin DM (2018). TIOTROPIUM RESPIMAT® REDUCES EPISODES OF ASTHMA WORSENING IN PRIMOTINA-ASTHMA®, IRRESPECTIVE OF BASELINE CHARACTERISTICS OR SEASON. Author URL.

Abbott C, Hilton E, Criner G, Dransfield M, Halpin D, Han M, Jones CE, Kilbride S, Lange P, Martinez F, et al (2018). TREATMENT EFFECTS OF FF/UMEC/VI VS FF/VI AND UMEC/VI IN COPD PATIENTS BY AIRFLOW LIMITATION SEVERITY: POST-HOC ANALYSES OF THE IMPACT STUDY. Author URL.

Wise R, Van Der Valk R, Hilton E, Criner G, Dransfield M, Halpin D, Han M, Jones CE, Kilbride S, Lange P, et al (2018). TREATMENT EFFECTS OF FF/UMEC/VI VS FF/VI AND UMEC/VI IN REVERSIBLE AND NONREVERSIBLE COPD PATIENTS: ANALYSES OF THE IMPACT STUDY. Author URL.

FitzGerald JM, Buhl R, Casale TB, El Azzi G, Engel M, Sigmund R, Halpin DM (2018). Tiotropium Respimat® Reduces Episodes of Asthma Worsening in PrimoTinA-asthma®, Irrespective of Baseline Characteristics or Season. Author URL.

Halpin D, Hamelmann E, Moroni-Zentgraf P, Van Hecke B, Unseld A, Kerstjens H (2017). COMPARATIVE RESPONSES IN LUNG FUNCTION MEASUREMENTS IN ADOLESCENTS AND ADULTS WITH MODERATE SYMPTOMATIC ASTHMA. Author URL.

Ming SWY, Haughney J, Ryan D, Small I, Lavorini F, Gruffydd-Jones K, Papi A, Singh D, Halpin D, Hurst J, et al (2017). COMPARISON OF THE INITIATION OF COPD TREATMENT WITH LICENSED FDC ICS/LABA TREATMENTS IN TERMS OF DISEASE CONTROL AND COST EFFECTIVENESS. Author URL.

Martinez F, Halpin D, Han MK, MiravitIes M, Rabe KF, Groenke L, Voss F, Singh D (2017). Clinically Important Deterioration Events in Chronic Obstructive Pulmonary Disease: a Post Hoc Analysis of the Relative Timing of Component Deterioration in the Uplift Study. Author URL.

Rastogi S, Bosnic-Antievich S, Pavord I, Roche N, Halpin D, Bjermer L, Usmani OS, Brusselle G, Ming SWY, Halim S, et al (2017). FENO AND BLOOD EOSINOPHILS AS BIOMARKERS IN PREDICTING ASTHMA EXACERBATIONS. Author URL.

Frith P, Halpin D, Moroni-Zentgraf P, Van Hecke B, Sigmund R, Kerstjens H (2017). FORCED VITAL CAPACITY RESPONSE TO TIOTROPIUM RESPIMAT® IN ADULT PATIENTS WITH SEVERE, MODERATE AND MILD SYMPTOMATIC ASTHMA. Author URL.

Hilton E, Brealey N, Birk R, Zhu C-Q, Criner GJ, Dransfield MT, Halpin D, Lomas DA, Lipson DA (2017). IMPROVEMENTS IN EXACERBATION RATES WITH SINGLE INHALER TRIPLE THERAPY VERSUS DUAL ICS/LABA THERAPY IN PATIENTS WITH ADVANCED CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD): SUBGROUP ANALYSES OF THE PHASE III FULFIL STUDY. Author URL.

Vogelberg C, Halpin D, Voelker B, Engel M, Luehmann R, Hamelmann E (2017). Once-daily tiotropium Respimat add-on therapy improves lung function in children with moderate symptomatic asthma, independent of the degree of airflow obstruction. Author URL.

Rabe KF, Halpin D, Martinez F, Miravitlles M, Singh D, Groenke L, Voss F, Han MK (2017). Predicting Long-Term Outcomes and Future Deterioration in COPD with a Composite Endpoint: Post Hoc Analysis of the Uplift Study. Author URL.

Halpin D, Han MK, Martinez F, Rabe KF, Singh D, Groenke L, Voss F, Miravitlles M (2017). Time-To-Event Analysis of a Composite Endpoint for Chronic Obstructive Pulmonary Disease: Post Hoc Analysis of the Uplift Study. Author URL.

Casale TB, Halpin DM, Engel M, Moroni-Zentgraf P, Muller A, Beeh K-M (2015). 24-HOUR EFFICACY OF TIOTROPIUM RESPIMAT® IN ASTHMA. Author URL.

Calverley P, Hallmann C, Metzdorf N, Grnke L, Mueller A, Halpin D (2015). LATE-BREAKING ABSTRACT: Tiotropium efficacy and exacerbation risk in patients with different blood eosinophil levels. Author URL.

Halpin D, Bateman ED, Paggiaro P, Bleecker ER, Engel M, Moroni-Zentgraf P, Schmidt H, Kerstjens HAM (2015). ONCE-DAILY TIOTROPIUM RESPIMAT (R) ADD-ON TO AT LEAST ICS MAINTENANCE THERAPY REDUCES EXACERBATION RISK IN PATIENTS WITH UNCONTROLLED SYMPTOMATIC ASTHMA. Author URL.

Doherty DE, Halpin D, Bateman E, Paggiaro P, Bleecker E, Engel M, Moroni-Zentgraf P, Schmidt H, Kerstjens HA (2015). ONCE-DAILY TIOTROPIUM RESPIMAT® ADD-ON TO AT LEAST ICS MAINTENANCE THERAPY REDUCES EXACERBATION RISK IN PATIENTS WITH UNCONTROLLED SYMPTOMATIC ASTHMA. Author URL.

Hynes G, Bakere H, McAleer C, Mitchelmore P, Hilton M, Halpin D (2015). The Benefits of an Integrated Vocal Cord Dysfunction Service in Treating a Subgroup of Patients with Difficult to Control Asthma. Author URL.

Chamberlain C, Williamson GR, Knight B, Daly M, Halpin DMG (2014). Investigating women’s experiences of asthma care in pregnancy: a qualitative study. Abstract.

Tashkin DP, Li N, Kleerup E, Halpin D, Decramer M, Celli BR, Elashoff R (2014). Long-Term Trends in Acute Bronchodilator Responses over 4 Years in Patients with Mild/moderate to Very Severe COPD: Post-Hoc Analysis of Data from the Uplift Trial. Author URL.

Halpin DMG, Paggiaro P, Bleecker E, Engel M, Moroni-Zentgraf P, Schmidt H, Kerstjens HAM (2014). ONCE-DAILY TIOTROPIUM RESPIMAT (R) ADD-ON TO AT LEAST ICS MAINTENANCE THERAPY REDUCES EXACERBATION RISK IN PATIENTS WITH UNCONTROLLED SYMPTOMATIC ASTHMA. Author URL.

Halpin D, Bateman E, Paggiaro P, Bleecker E, Engel M, Moroni-Zentgraf P, Schmidt H, Kerstjens H (2014). Once-daily tiotropium respimat add-on to at least ICS maintenance therapy reduces exacerbation risk in patients with uncontrolled symptomatic asthma. Author URL.

Halpin DMG, Dahl R, Hallmann C, Leimer I, Mueller A, Tashkin DP (2014). TIOTROPIUM HANDIHALER (R) AND RESPIMAT (R) IN COPD: a SAFETY ANALYSIS ON POOLED DATA. Author URL.

Paggiaro P, Halpin DMG, Buhl R, Engel M, Zubek VB, Blahova Z, Moroni-Zentgraf P, Pizzichini E (2014). TIOTROPIUM RESPIMAT (R) ADD-ON TO INHALED CORTICOSTEROIDS IMPROVES LUNG FUNCTION IN PATIENTS WITH SYMPTOMATIC MILD ASTHMA: RESULTS FROM a PHASE III TRIAL. Author URL.

Halpin DMG, Dahl R, Hallmann C, Leimer I, Kupas K, Mueller A, Tashkin DP (2014). Tiotropium Handihaler® and Respimat® in COPD: a Safety Analysis on Pooled Data. Author URL.

Paggiaro P, Halpin DMG, Buhl R, Engel M, Zubek V, Blahova Z, Moroni-Zentgraf P, Pizzichini E (2014). Tiotropium Respimat® Add-On to Inhaled Corticosteroids Improves Lung Function in Patients with Symptomatic Mild Asthma: Results from a Phase III Trial. Author URL.

Tashkin DP, Li N, Halpin D, Kleerup E, Decramer M, Celli BR, Elashoff R (2013). Comparison of the Annual Rates of Change in Fev1 and FVC Determined from Serial Measurements of the Pre- Vs. Post-Bronchodilator Fev1 and FVC over 4 Years in Moderate Yo Very Severe COPD: Results from the Uplift Trial. Author URL.

Decramer M, Celli BR, Tashkin DP, Martin A, Leimer I, Metzdorf N, Halpin DM (2013). Efficacy of Tiotropium in a 4 Years Study Analyzed According to New Gold Abcd Severity Grading. Author URL.

Halpin DMG, Holmes S, Calvert J, McInerney D (2013). FINDING THE MISSING MILLIONS: CASE FINDING FOR COPD IN PEOPLE ATTENDING OTHER LONG TERM CONDITION CLINICS IN PRIMARY CARE. Author URL.

Chamberlain C, Williamson GR, Knight B, Daley M, Halpin DM (2013). INVESTIGATING WOMEN'S EXPERIENCES OF ASTHMA CARE IN PREGNACY: a QUALITATIVE STUDY. Author URL.

Bernstein JA, Kerstjens HAM, Moroni-Zentgraf P, Engel M, Schmidt H, Halpin DMG (2013). Once-Daily Tiotropium is Well Tolerated as Add-On to Standard Treatment for Patients with Symptomatic Asthma Despite Receiving Inhaled Corticosteroids and Long-Acting β2-Agonists. Author URL.

Halpin DMG (2013). PREVALENCE OF SERUM EOSINOPHILIA AT TIME OF ADMISSION WITH AN EXACERBATION OF COPD. Author URL.

Halpin DMG, Bateman ED, Tashkin DP, Engel M, Dahl R, Paggiaro P, Beck E, Vandewalker M, Seibold W, Moroni-Zentgraf P, et al (2013). TIOTROPIUM DECREASES THE RISK OF EXACERBATIONS IN PATIENTS WITH SYMPTOMATIC ASTHMA REGARDLESS OF BASELINE CHARACTERISTICS INCLUDING MARKERS OF ALLERGIC STATUS. Author URL.

Halpin DMG, Bateman ED, Moroni-Zentgraf P, Engel M, Schmidt H, Kerstjens HAM (2013). TIOTROPIUM IS EFFECTIVE IN PATIENTS WITH SEVERE ASTHMA WITHOUT EVIDENCE OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE. Author URL.

Halpin DM, Bateman ED, Moroni-Zentgraf P, Engel M, Schmidt H, Kerstjens HAM (2013). Tiotropium is Effective in Patients with Severe Asthma Without Evidence of Chronic Obstructive Pulmonary Disease. Author URL.

Halpin DMG, Batten P, Chamberlain C (2012). COPD DISCHARGE BUNDLES: THE EXETER EXPERIENCE 2011-12. Author URL.

Halpin D, Decramer M, Celli B, Martin A, Leimer I, Metzdorf N, Tashkin D (2012). Effectiveness of tiotropium in low-risk patients according to new GOLD severity grading. Author URL.

Halpin D, Decramer M, Celli B, Martin A, Leimer I, Metzdorf N, Tashkin D (2012). Impact of a single chronic obstructive pulmonary disease (COPD) exacerbation on lung function decline: Analysis of UPLIFT®. Author URL.

Masoli M, Castell B, Halpin D, Chamberlain C, Stone R, Shrimanker R, Dobson L, Cutland K, Suntharalingam J, Carver R, et al (2012). Omalizumab improves lung function in severe persistent allergic (IgE-mediated) asthma patients: Pooled data from 5 UK centres. Author URL.

Bakere H, Ward A, Halpin D (2010). Management of acute severe asthma, optimisation of therapy and identification of patients potentially suitable for anti-IgE therapy: relevance of admitting team. Author URL.

Gott M, Gardiner C, Payne S, Small N, Seamark D, Halpin D (2009). Barriers to advance care planning for older people with chronic obstructive pulmonary disease: Patient and professional perspectives. Author URL.

Halpin D, Gardiner C, Gott M, Barnes S, Payne S, Ruse C, Small N, Seamark D (2009). Discussing Prognosis in COPD: Findings from a Qualitative Study with Clinicians in the UK. Author URL.

Halpin D, Laing-Morton T, Levy M, Marno P (2009). EFFECT OF AN INNOVATIVE AUTOMATED INTERACTIVE HEALTH FORECAST ALERT SYSTEM ON RATE OF EXACERBATIONS OF COPD. Author URL.

Dodd JW, Tribe HC, Halpin DM (2007). Appropriateness of emergency oxygen therapy for COPD patients. Author URL.

Halpin DMG, Miravitlles M (2006). Chronic obstructive pulmonary disease: the disease and its burden to society. Abstract.

Halpin DMG (2006). Health economics of chronic obstructive pulmonary disease. Abstract.

Bryden C, Bird W, Halpin DM, Levy ML (2006). Seasonality in chronic obstructive pulmonary disease emergency admissions to hospital, and predictability using surveillance for influenza-like illness. Author URL.

External Engagement and Impact

Awards

Elected as a Fellow of European Respiratory Society in 2018 in recognition of lifetime excellence and contributions to research, education and clinical leadership in respiratory medicine.

Committee/panel activities

Member, Board of Directors & Science Committee, Global Obstructive Lung Disease Initiative (GOLD) since 2014
Vice Chair, South West Clinical Senate Council since 2015
Former Chair & Clinical Advisor, NICE COPD Guideline Group
Former Chair, NICE Anaemia management in chronic kidney disease Guideline Group
Former External Examiner, MSc & Diploma in Respiratory Medicine, Imperial College, London
Former Chair, NICE Chronic Kidney Disease Guideline Group
Former Chair, Met Office COPD Health Forecasting Advisory Group
Former Member, NICE COPD Quality Standards Topic Expert Group
Former Respiratory Clinical Lead, NHS South West
Former Member, Department of Health COPD Commissioning Reference Group

Editorial responsibilities

Former Associate Editor Thorax

Invited lectures

Chinese College of Allergy & Asthma, 2018
American Thoracic Society, 2018
Asian Pacific Society of Respirology, Taipei, 2018
COPD 11, Birmingham, 2018
Taiwan Pulmonolgy Society, Taichung, 2018
Pneumo UPDATE, Budapest, 2018
Latin American Expert Forum, Panama, 2018
GOLD 2019 Meeting, Philadelphia, 2018
European Respiratory Society, Paris, 2018
Brazilian Respiratory Expert Forum, Sao Paulo, 2018
Korean National Respiratory Congress, Seoul
2019 International Meeting on Asthma, COPD and Concomitant Disorders, Florence
American Thoracic Society, 2019
COPD Forum, Beijing, 2019
Pneumo UPDATE, Prague , 2019
Chinese Thoracic Society Satellite Meeting, Guangzhou, 2019
Malaysian Thoracic Society COPD Meeting, Kuala Lumpur, 2019
COPD Forum, Singapore , 2019
CUHK Advances in Medicine, Hong Kong, 2019
COPD Forum Changdu, 2020
SEPAR COVID meeting (virtual), 2020
American Thoracic Society (virtual), 2020
Taiwan Airway Forum (virtual), 2020
Hong Kong Thoracic Society (virtual), 2020
Indian COPD Webinar, 2020

Edit Profile